var data={"title":"Chemotherapy hepatotoxicity and dose modification in patients with liver disease","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chemotherapy hepatotoxicity and dose modification in patients with liver disease</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/contributors\" class=\"contributor contributor_credentials\">Justin Floyd, DO</a></dd><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/contributors\" class=\"contributor contributor_credentials\">Thomas Archibald Kerr, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/contributors\" class=\"contributor contributor_credentials\">Reed E Drews, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/contributors\" class=\"contributor contributor_credentials\">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 16, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients undergoing cytotoxic chemotherapy require careful assessment of liver function both prior to and during therapy. Potential interactions between the liver and chemotherapy fall into two categories:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Direct chemotherapy-induced hepatotoxicity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potentiation of preexisting liver disease, especially viral hepatitis. Altered hepatic drug metabolism due to underlying liver disease can result in higher or more persistent drug levels, thereby causing increased systemic toxicity (particularly myelosuppression) or worsening of liver function because of chemotherapy-induced hepatotoxicity.</p><p/><p>The interrelationship between the liver and chemotherapy is reviewed here. General aspects of drug metabolism and patterns of hepatic injury are discussed separately, as is reactivation of hepatitis B (HBV) viral infection in patients treated with immunosuppressive therapy, and hepatotoxicity associated with checkpoint inhibitor immunotherapy (<a href=\"topic.htm?path=ipilimumab-drug-information\" class=\"drug drug_general\">ipilimumab</a>, <a href=\"topic.htm?path=pembrolizumab-drug-information\" class=\"drug drug_general\">pembrolizumab</a>, <a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">nivolumab</a>), as used for advanced melanoma and non-small cell lung cancer. (See <a href=\"topic.htm?path=drugs-and-the-liver-metabolism-and-mechanisms-of-injury\" class=\"medical medical_review\">&quot;Drugs and the liver: Metabolism and mechanisms of injury&quot;</a> and <a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">&quot;Drug-induced liver injury&quot;</a> and <a href=\"topic.htm?path=hepatitis-b-virus-reactivation-associated-with-immunosuppressive-therapy\" class=\"medical medical_review\">&quot;Hepatitis B virus reactivation associated with immunosuppressive therapy&quot;</a> and <a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy#H645631\" class=\"medical medical_review\">&quot;Toxicities associated with checkpoint inhibitor immunotherapy&quot;, section on 'Hepatotoxicity'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">GENERAL ASPECTS OF DRUG-INDUCED HEPATOTOXICITY</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Mechanisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most hepatotoxic drug reactions are idiosyncratic and classified mechanistically either as immunologic (hypersensitivity) or metabolic [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/1\" class=\"abstract_t\">1</a>]. These reactions typically are neither dose dependent nor predictable. (See <a href=\"topic.htm?path=drugs-and-the-liver-metabolism-and-mechanisms-of-injury#H14\" class=\"medical medical_review\">&quot;Drugs and the liver: Metabolism and mechanisms of injury&quot;, section on 'Mechanisms of drug-induced hepatotoxicity'</a>.)</p><p>While the reaction to many chemotherapy drugs is manifested by hepatocellular injury, inflammation, <span class=\"nowrap\">and/or</span> cholestasis, other agents cause endothelial damage or thrombosis leading to vascular complications such as hepatic veno-occlusive disease (VOD, also called hepatic sinusoidal obstruction syndrome [SOS]).</p><p class=\"headingAnchor\" id=\"H2739719\"><span class=\"h3\">Liposomal drug formulations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Liposomal drug delivery systems have been utilized to improve the pharmacologic characteristics of chemotherapeutics and antibiotics, and improve drug delivery to optimal sites of action. Nevertheless, concerns have been raised about altered toxicity profiles with these preparations relative to non-encapsulated drug forms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a case control study of patients undergoing hematopoietic cell transplant, use of <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> (L-AMB) was associated with a <strong>higher</strong> rate of elevated liver enzymes compared with conventional <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (AMB-D) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/2\" class=\"abstract_t\">2</a>]. However, an autopsy study of 64 patients treated before death with either L-AMB or <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">amphotericin B lipid complex</a> (ABLC) failed to reveal any clear histologic evidence of hepatotoxicity in either group, despite well-characterized elevations in liver enzymes with administration of these medicines [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/3\" class=\"abstract_t\">3</a>]. These data suggest that elevated liver enzymes associated with liposomal drug formulations such as amphotericin B may not reflect severe histologic injury.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On the other hand, animal studies have suggested that sterically stabilized liposomal encapsulation of 6-mercaptopurine (6-MP) is associated with decreased hepatoxicity compared with conventional liposomal formulations [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/4\" class=\"abstract_t\">4</a>].</p><p/><p>As liposomal drug delivery approaches become more common and diverse, patterns of hepatotoxicity may be altered.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Hepatic vascular injury</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>SOS, previously called VOD, is a pattern of liver injury that is caused by nonthrombotic obliteration of small intrahepatic veins by subendothelial fibrin. SOS is associated with congestion and potentially fatal necrosis of centrilobular hepatocytes.</p><p>SOS occurs most frequently in patients undergoing hematopoietic cell transplantation. Most cases are thought to be drug-induced, and the drugs most commonly implicated are those that undergo hepatic metabolism. (See <a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-hepatic-sinusoidal-obstruction-syndrome-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation&quot;</a>.)</p><p>SOS has occasionally been reported with non-myeloablative doses of <a href=\"topic.htm?path=dacarbazine-drug-information\" class=\"drug drug_general\">dacarbazine</a> (DTIC) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/5-11\" class=\"abstract_t\">5-11</a>], including patients treated with ABVD (<a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>, <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a>, <a href=\"topic.htm?path=vinblastine-drug-information\" class=\"drug drug_general\">vinblastine</a>, DTIC) for Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/12,13\" class=\"abstract_t\">12,13</a>], and with <a href=\"topic.htm?path=dactinomycin-drug-information\" class=\"drug drug_general\">dactinomycin</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/11\" class=\"abstract_t\">11</a>], 6-thioguanine (6-TG) or 6-MP [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/14,15\" class=\"abstract_t\">14,15</a>], and <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> (AZ) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/16,17\" class=\"abstract_t\">16,17</a>].</p><p>A pattern of hepatic vascular injury similar to that seen in SOS has been noted in patients receiving combinations of <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a> (FU) and <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> with <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a> or <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a> for neoadjuvant (downstaging) therapy prior to the resection of colorectal cancer liver metastases. Findings at the time of liver resection include steatosis, hepatic vascular injury, and nodular regenerative hyperplasia (now termed idiopathic noncirrhotic portal hypertension [including nodular regenerative hyperplasia]). Because of this injury pattern, it is generally recommended that the duration of neoadjuvant therapy be limited to the fewest number of cycles needed to render patients resectable. (See <a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation&quot;</a> and <a href=\"topic.htm?path=noncirrhotic-portal-hypertension#H2\" class=\"medical medical_review\">&quot;Noncirrhotic portal hypertension&quot;, section on 'Idiopathic noncirrhotic portal hypertension (including nodular regenerative hyperplasia)'</a> and <a href=\"topic.htm?path=management-of-potentially-resectable-colorectal-cancer-liver-metastases#H5842613\" class=\"medical medical_review\">&quot;Management of potentially resectable colorectal cancer liver metastases&quot;, section on 'Chemotherapy-related liver toxicity'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Irradiation plus chemotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although radiation to the liver is itself hepatotoxic, otherwise tolerable doses of radiation therapy to the right upper quadrant can induce severe hepatic injury when combined with systemic doses of normally nonhepatotoxic chemotherapeutic agents. This has been described most often in patients treated concurrently with hepatic radiation and <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/18,19\" class=\"abstract_t\">18,19</a>], <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/20\" class=\"abstract_t\">20</a>], and <a href=\"topic.htm?path=dactinomycin-drug-information\" class=\"drug drug_general\">dactinomycin</a>. (See <a href=\"#H31\" class=\"local\">'Dactinomycin'</a> below.)</p><p>In an illustrative series, 35 patients with lymphoma received concurrent monthly <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> and relatively low-dose liver irradiation (total dose, 15 to 25 Gy) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/18\" class=\"abstract_t\">18</a>]. Ten of 35 patients developed severe hepatotoxicity (aspartate transaminase [AST] greater than three times normal, clinical evidence of liver failure, one fatal), and nine had moderate toxicity.</p><p>Reactivation or exacerbation of radiation-induced hepatic damage is a likely mechanism since all of these drugs have been associated with a radiation &quot;recall&quot; reaction in previously irradiated tissues. (See <a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents#H463131030\" class=\"medical medical_review\">&quot;Cutaneous side effects of conventional chemotherapy agents&quot;, section on 'Radiation recall and enhancement'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Clinical presentation and diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical presentation of chemotherapy-related hepatotoxicity can range from asymptomatic biochemical abnormalities to an acute illness with jaundice that resembles viral hepatitis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/21\" class=\"abstract_t\">21</a>].</p><p>The severity of liver injury is primarily assessed by measurement of the serum aminotransferases (AST and alanine aminotransferase [ALT]), bilirubin, and alkaline phosphatase. The pattern of abnormalities on these tests is more informative than elevation of any individual test. Elevation of aminotransferases (AST, ALT) typically indicates hepatocellular injury, while increases in bilirubin and alkaline phosphatase suggest cholestasis. (See <a href=\"topic.htm?path=liver-biochemical-tests-that-detect-injury-to-hepatocytes\" class=\"medical medical_review\">&quot;Liver biochemical tests that detect injury to hepatocytes&quot;</a>.)</p><p>Standardized criteria have been developed by the National Cancer Institute (NCI) and World Health Organization (WHO) to quantify or grade the severity of treatment-related abnormalities in the liver function tests (LFTs) in patients undergoing chemotherapy (<a href=\"image.htm?imageKey=ONC%2F77533\" class=\"graphic graphic_table graphicRef77533 \">table 1</a>).</p><p>The distinction between drug-induced hepatotoxicity due to chemotherapy and other causes of liver injury can be difficult.</p><p>The differential diagnosis includes progressive tumor, coexisting hepatic disease, and adverse effects of other drugs which produce similar clinical features and abnormalities in the LFTs [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/22,23\" class=\"abstract_t\">22,23</a>]. Features suggesting toxicity due to chemotherapy include lack of prior illness, clinical symptoms or biochemical abnormalities developing after drug administration, and improvement after discontinuation of the cytotoxic agent.</p><p>Abdominal ultrasound or computed tomography (CT) may be needed to differentiate drug toxicity from biliary, vascular, or tumor-related conditions. A liver biopsy is seldom necessary to characterize or stage acute hepatotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/24\" class=\"abstract_t\">24</a>]. (See <a href=\"topic.htm?path=approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests\" class=\"medical medical_review\">&quot;Approach to the patient with abnormal liver biochemical and function tests&quot;</a> and <a href=\"topic.htm?path=approach-to-liver-biopsy\" class=\"medical medical_review\">&quot;Approach to liver biopsy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Natural history</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The natural history of chemotherapy hepatotoxicity is variable. Some agents cause reversible toxicity while others are associated with a progressive course that can lead to fibrosis or cirrhosis despite drug discontinuation. Toxicity will generally recur upon reintroduction of the offending substance if the reaction was immunologically based. In this situation, rechallenge is usually not recommended.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Impact of preexisting liver disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Susceptibility to chemotherapy-induced liver injury may be increased by the presence of hepatobiliary metastases, immune compromise, <span class=\"nowrap\">viral/autoimmune</span> hepatitis, nutritional deficiencies, or the use of parenteral nutrition.</p><p>Patients with a preexisting liver disease should undergo a full diagnostic workup prior to chemotherapy to elucidate the cause and severity of the liver disease. Therapy of any coexisting liver disorder should be optimized to minimize the potential for chemotherapy-induced complications. (See <a href=\"topic.htm?path=approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests\" class=\"medical medical_review\">&quot;Approach to the patient with abnormal liver biochemical and function tests&quot;</a>.)</p><p>Clinical decision-making must incorporate the need for expedient treatment of the patient's malignancy. Some drugs will need to be avoided while dose reduction may be appropriate for other agents in patients with significant liver disease, regardless of its etiology.</p><p>Infection with hepatitis B (HBV) or hepatitis C (HCV) is a common disorder that can be exacerbated with cytotoxic chemotherapy.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Hepatitis B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HBV infection with a high viral load prior to treatment is an adverse factor for survival and may be associated with a higher incidence of severe hepatitis during chemotherapy [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/25\" class=\"abstract_t\">25</a>]. In addition, multiple reports have documented a significantly increased incidence of HBV reactivation in patients receiving certain types of myelosuppressive systemic chemotherapy, notably anti-CD20 therapies (ie, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, <a href=\"topic.htm?path=ofatumumab-drug-information\" class=\"drug drug_general\">ofatumumab</a>, and <a href=\"topic.htm?path=obinutuzumab-drug-information\" class=\"drug drug_general\">obinutuzumab</a>). (See <a href=\"topic.htm?path=hepatitis-b-virus-reactivation-associated-with-immunosuppressive-therapy#H865802126\" class=\"medical medical_review\">&quot;Hepatitis B virus reactivation associated with immunosuppressive therapy&quot;, section on 'Very high risk'</a>.)</p><p>The magnitude of risk for less myelosuppressive chemotherapy regimens, as are used for treatment of solid tumors, has not been well established [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/26,27\" class=\"abstract_t\">26,27</a>]. In a systematic review of 26 observational studies and randomized trials in patients with chronic or resolved HBV receiving chemotherapy for solid tumors, the risk of reactivation for patients with chronic HBV (ie, HBsAg-positive) ranged from 4 to 68 percent, with most studies reporting a reactivation risk greater than 10 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/26\" class=\"abstract_t\">26</a>]. For individuals with resolved HBV infection (defined as HBsAg-negative, anti-HBc-positive, HBV DNA-negative), reactivation rates ranged from 0.3 to 9.0 percent. Antiviral therapy administered during chemotherapy reduced the risk of HBV reactivation by approximately 90 percent, and also reduced HBV-related hepatitis and the need for chemotherapy interruption.</p><p>The American Association for the Study of Liver Diseases (AASLD) has published guidelines for evaluation and treatment of patients with chronic HBV infection, including recommendations regarding antiviral prophylaxis for HBV-infected patients undergoing chemotherapy [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/28\" class=\"abstract_t\">28</a>]. They suggest that all patients receiving potentially myelosuppressive chemotherapy be screened for HBV infection by measuring HBsAg and hepatitis B core antibody (anti-HBc) prior to initiation of treatment; if either test is positive, recommendations for use of prophylactic antiviral therapy versus monitoring vary according to the individual risk profile of the specific agents.</p><p>However, this recommendation for universal screening remains controversial, and universal screening has not been widely adopted by many oncologists, despite the position of the AASLD and other groups. A year 2015 provisional clinical opinion from the American Society of Clinical Oncology (ASCO) recommends screening patients only if they are at high risk for HBV infection (birthplace in a country with &ge;2 percent HBV prevalence, household or sexual contact with persons with HBV infection, high-risk behaviors such as IV drug use, HIV infection), or if highly immunosuppressive therapy is used (eg, hematopoietic cell transplantation or use of an anti-CD20 agent such as <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, <a href=\"topic.htm?path=ofatumumab-drug-information\" class=\"drug drug_general\">ofatumumab</a>, or <a href=\"topic.htm?path=obinutuzumab-drug-information\" class=\"drug drug_general\">obinutuzumab</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/29\" class=\"abstract_t\">29</a>]. They consider that the current data are insufficient to justify screening of all patients initiating chemotherapy. Additional information will be forthcoming from a prospective trial being conducted by the <a href=\"https://clinicaltrials.gov/ct2/show/NCT01946516?term=SWOG+and+hepatitis+B+virus&rank=1&amp;token=dldXWdrh5EA6Gr8uCGGlS3/RhAhfFkbBXq/tuvrCy8YPQw4Ro1idmfkJKjfgAmu3VhkzTx5Wk37xLAwK8x/d0C2Hyu/n0+wRDD5UrZs4zlphF3EhoI1KIMznI20h49zJ&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">Southwest Oncology Group</a>, which is evaluating the prevalence of viral infection, the type and range of adverse chemotherapy effects among patients with viral infection, and the cost-effectiveness of viral screening among newly diagnosed cancer patents. At present, oncologists (including the authors of this topic review) remain divided on this issue. This subject is discussed in detail elsewhere. (See <a href=\"topic.htm?path=hepatitis-b-virus-reactivation-associated-with-immunosuppressive-therapy\" class=\"medical medical_review\">&quot;Hepatitis B virus reactivation associated with immunosuppressive therapy&quot;</a>.)</p><p>Given the risk of HBV reactivation with the use of the anti-CD20 agents <a href=\"topic.htm?path=ofatumumab-drug-information\" class=\"drug drug_general\">ofatumumab</a>, <a href=\"topic.htm?path=obinutuzumab-drug-information\" class=\"drug drug_general\">obinutuzumab</a>, and <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, the US prescribing information for all three drugs includes boxed warning information concerning screening for HBV for all patents initiating treatment with these agents and prophylactic treatment of all who are positive for either HBsAg or anti-HBc. Monitoring for reactivation is recommended during therapy and for several months following completion of therapy. If reactivation occurs, treatment should be stopped and appropriate therapy initiated for HBV.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Hepatitis C</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although severe hepatitis from reactivation of HCV infection has been documented in case reports [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/30-32\" class=\"abstract_t\">30-32</a>], it seems to be less common than HBV activation [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/33\" class=\"abstract_t\">33</a>], and the relationship between immunosuppressive chemotherapy and viral reactivation is less clear than for HBV.</p><p>In three large series of patients who had anti-HCV antibodies, treatment for hematologic malignancies was associated with mild LFT abnormalities in 18 percent or fewer [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/34-36\" class=\"abstract_t\">34-36</a>]. In another report of 33 patients, 32 of whom had chronic disease as manifested by positivity for HCV RNA, transaminases increased in 55 percent; however, only one patient had a severe flare of underlying hepatitis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/37\" class=\"abstract_t\">37</a>]. Thus, although chemotherapy may be associated with elevations in LFTs in patients with HCV, this does not appear to be a major issue except for those with preexisting decompensated liver disease.</p><p>Infection with HCV does appear to increase the risk of developing SOS in patients undergoing high dose chemotherapy and hematopoietic stem cell transplantation. (See <a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation#H5\" class=\"medical medical_review\">&quot;Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation&quot;, section on 'Preexisting liver disease'</a>.)</p><p>Patients with chronic HCV infection who are receiving chemotherapy should undergo serial monitoring of LFTs, and if there is no dramatic change, continued chemotherapy treatment without dose modification is appropriate.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">CYTOTOXIC AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Altered drug metabolism due to hepatic dysfunction can result in systemic toxicity due to higher or more persistent drug levels. Knowledge of the pharmacokinetics of antineoplastic agents in patients with liver disease is incomplete and has generally been derived from small numbers of heterogeneous patients with only mild to moderate liver dysfunction. As a result, guidelines for dose adjustment are largely empirical (<a href=\"image.htm?imageKey=ONC%2F69104\" class=\"graphic graphic_table graphicRef69104 \">table 2</a>).</p><p>Dose adjustments must be viewed in the appropriate clinical context. Patients with metastatic disease are rarely cured, and initial chemotherapy doses that could lead to excessive treatment-related toxicity should be avoided. If liver function tests (LFTs) are abnormal because of extensive liver metastases, and the hepatic metastases respond to treatment, doses can often be increased after the initial courses of therapy.</p><p>In this section, both the hepatotoxicity of specific chemotherapy agents and recommended dose modifications due to altered hepatic metabolism are discussed.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Alkylating agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As a group, alkylating agents are uncommonly associated with hepatotoxicity. Although the mechanism of liver damage associated with these agents is unclear, depletion of glutathione and oxidative injury have been implicated [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/38\" class=\"abstract_t\">38</a>]. With the possible exception of <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> and <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a>, patients receiving alkylating agents usually do not require dose reduction because of underlying liver disease.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Cyclophosphamide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">Cyclophosphamide</a> is metabolized by the liver to 4-hydroxycyclophosphamide, which is in equilibrium with its acyclic tautomeric form, aldophosphamide. In susceptible cells, nonenzymatic cleavage of aldophosphamide yields phosphoramide mustard and acrolein, which are thought to be the cytotoxic metabolites.</p><p>Despite its conversion in the liver to an active metabolite, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> is infrequently hepatotoxic. Abnormal LFTs attributed to the drug have only been reported occasionally, and this effect is probably due to an idiosyncratic reaction rather than direct toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/39-43\" class=\"abstract_t\">39-43</a>].</p><p>In patients undergoing treatment for vasculitis, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> has been associated with liver necrosis when its administration was preceded by <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> (AZ) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/44\" class=\"abstract_t\">44</a>]. In two of the four affected patients, cyclophosphamide had previously been administered as a single agent without hepatic injury, suggesting that an interaction between the drugs was responsible for this toxicity. (See <a href=\"topic.htm?path=general-principles-of-the-use-of-cyclophosphamide-in-rheumatic-diseases\" class=\"medical medical_review\">&quot;General principles of the use of cyclophosphamide in rheumatic diseases&quot;</a>.)</p><p>Increased toxicity has not been reported in patients with hepatic dysfunction [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/45,46\" class=\"abstract_t\">45,46</a>]. Nevertheless, some clinicians recommend a 25 percent dose reduction in dose for patients with a serum bilirubin 3.1 to 5 <span class=\"nowrap\">mg/dL</span> or aspartate transaminase (AST) greater than three times the upper limit of normal (ULN), and not giving the drug if the bilirubin is &ge;5 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47\" class=\"abstract_t\">47</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Ifosfamide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">Ifosfamide</a> has been uncommonly associated with hepatotoxicity; in a total of 2070 patients from 30 studies of single agent ifosfamide, the reported incidence of liver dysfunction was 3 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/48,49\" class=\"abstract_t\">48,49</a>].</p><p>Dose reductions are probably not necessary for patients with altered liver function. However, <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a> is extensively hepatically metabolized, and some clinicians recommend a 25 percent dose reduction for patients with significant hepatic dysfunction (serum AST &gt;300 int. <span class=\"nowrap\">unit/L</span> or bilirubin &gt;3 <span class=\"nowrap\">mg/dL)</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47,50\" class=\"abstract_t\">47,50</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information.</p><p class=\"headingAnchor\" id=\"H1743491205\"><span class=\"h3\">Temozolomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">Temozolomide</a> is an orally active alkylating agent used predominantly for the treatment of adults with primary brain tumors. Patients with mild to moderate hepatic dysfunction have similar pharmacokinetics compared to those with normal function, although patients with severe hepatic dysfunction have not been studied [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/51\" class=\"abstract_t\">51</a>].</p><p>Fatal and severe hepatotoxicity has been reported in patients receiving <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">temozolomide</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/52-55\" class=\"abstract_t\">52-55</a>]. The United States prescribing information was revised in May 2014 to recommend that LFTs be performed at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of temozolomide [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/56\" class=\"abstract_t\">56</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Other alkylating agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other alkylating agents generally are not dependent upon the liver for the metabolism and are not frequently associated with hepatotoxicity.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nitrogen mustard &ndash; Nitrogen mustard is rapidly degraded and does not require hepatic metabolism for its disposition. Nitrogen mustard has not been associated with hepatotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/57\" class=\"abstract_t\">57</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">Melphalan</a> &ndash; Melphalan is rapidly hydrolyzed in plasma, and approximately 15 percent is excreted unchanged in the urine; the remainder is metabolized and excreted in stool. Although melphalan is not associated with hepatotoxicity at usual oral doses, transient LFT abnormalities have been reported with the higher doses used in the setting of hematopoietic stem cell transplantation [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/58,59\" class=\"abstract_t\">58,59</a>]. (See <a href=\"topic.htm?path=preparative-regimens-for-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Preparative regimens for hematopoietic cell transplantation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">Chlorambucil</a> &ndash; Chlorambucil rarely causes hepatotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/60,61\" class=\"abstract_t\">60,61</a>]. In one autopsy series of 181 patients with hematologic malignancies, three of six cases of cholestatic jaundice were attributed to chlorambucil [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/60\" class=\"abstract_t\">60</a>]. In a second case report, drug-induced hepatotoxicity and skin rash recurred upon rechallenge with chlorambucil [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/61\" class=\"abstract_t\">61</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=busulfan-drug-information\" class=\"drug drug_general\">Busulfan</a> &ndash; Busulfan is rapidly cleared from the blood after intravenous administration and almost entirely excreted in the urine as methanesulfonic acid; hepatic metabolism is unimportant. At standard doses, busulfan rarely causes hepatic dysfunction, although it has been linked to some cases of cholestatic hepatitis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/62,63\" class=\"abstract_t\">62,63</a>].</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=busulfan-drug-information\" class=\"drug drug_general\">Busulfan</a> is a common component of preparative regimens for hematopoietic cell transplantation. In this setting, busulfan has been associated with hepatic sinusoidal obstruction syndrome (SOS). (See <a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=bendamustine-drug-information\" class=\"drug drug_general\">Bendamustine</a> &#9472; Bendamustine undergoes hepatic metabolism, and the manufacturer recommends that the drug not be administered to patients with preexisting moderate to severe hepatic impairment (transaminases &ge;2.5 X ULN or total bilirubin &ge;1.5 X ULN).</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Nitrosoureas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The nitrosoureas <a href=\"topic.htm?path=carmustine-drug-information\" class=\"drug drug_general\">carmustine</a> (BCNU), <a href=\"topic.htm?path=lomustine-drug-information\" class=\"drug drug_general\">lomustine</a> (CCNU), and <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a> appear to function as both alkylating and carbamoylating agents. Like other alkylating agents, nitrosoureas deplete hepatic stores of glutathione [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/64\" class=\"abstract_t\">64</a>], which may increase the risk of oxidative injury.</p><p>Increases in LFTs occur in 20 to 25 percent of carmustine-treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/65,66\" class=\"abstract_t\">65,66</a>], and the onset may be delayed up to four months following treatment. At conventional doses, LFT elevations are usually mild and revert to normal over a brief period, although fatalities have been reported. The hepatotoxic effects of CCNU are similar [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/67\" class=\"abstract_t\">67</a>].</p><p>Streptozocin-induced hepatotoxicity is manifest primarily as hepatocellular injury and has been reported in 15 to 67 percent of treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/68,69\" class=\"abstract_t\">68,69</a>]. These changes appear within a few days to weeks after treatment and are usually asymptomatic; rapid, complete resolution is the rule.</p><p>Although dosing adjustment may be necessary in patients with severe hepatic dysfunction, no guidelines have been published for any of the nitrosoureas. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information. Hepatic function should be closely monitored during treatment.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Antimetabolites</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The hepatotoxic potential of antimetabolites is variable. Hepatic metabolism plays an important role in the disposition of many drugs in this class, and dose reduction is frequently necessary in patients with liver dysfunction.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Cytarabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatotoxicity from <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> has been difficult to establish because it is used for treatment of leukemia, and these patients frequently undergo transfusions of blood products, are subject to infections, receive multiple medications, and are often not candidates for liver biopsy because of prolonged thrombocytopenia. Abnormal LFTs were reported in 37 of 85 leukemic patients receiving cytarabine in an early series, but many patients had preexisting LFT abnormalities, potentially confounding factors (eg, sepsis or hemolysis), or spontaneous resolution of biochemical abnormalities despite continuation of therapy [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/70\" class=\"abstract_t\">70</a>].</p><p>In more contemporary reports, <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> infrequently causes histologically proven cholestasis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/71,72\" class=\"abstract_t\">71,72</a>]. Furthermore, transiently abnormal LFTs developed in 24 of 27 patients undergoing high-dose cytarabine by 72-hour continuous infusion in one series [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/73\" class=\"abstract_t\">73</a>]. These effects are reversible and generally not dose-limiting [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/73-75\" class=\"abstract_t\">73-75</a>].</p><p>The liver is the primary site for the detoxification of much of the administered dose of <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>. Doses should be reduced in patients with severe hepatic dysfunction in order to avoid an increased risk of treatment-related central nervous system toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/76\" class=\"abstract_t\">76</a>]. (See <a href=\"topic.htm?path=overview-of-neurologic-complications-of-non-platinum-cancer-chemotherapy#H28\" class=\"medical medical_review\">&quot;Overview of neurologic complications of non-platinum cancer chemotherapy&quot;, section on 'Cytarabine'</a>.)</p><p>Some clinicians recommend a 50 percent decrease in the dose in patients with any aminotransferase elevation [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47\" class=\"abstract_t\">47</a>]. However, this is not routinely done in potentially curative settings such as induction therapy for acute myelogenous leukemia. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Fluorouracil and capecitabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following intravenous administration, approximately 10 percent of administered <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a> (FU) is excreted unchanged in the urine, while the remainder is catabolized by dihydropyrimidine dehydrogenase (DPD), primarily in the liver. Both the toxicity and the antitumor effect are potentiated if catabolism is blocked by inhibition or inactivity of DPD. (See <a href=\"topic.htm?path=enterotoxicity-of-chemotherapeutic-agents\" class=\"medical medical_review\">&quot;Enterotoxicity of chemotherapeutic agents&quot;</a>.)</p><p>Only rare reports of hepatotoxicity have been noted with FU [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/77\" class=\"abstract_t\">77</a>]. More hepatotoxicity has been reported when FU is administered in combination with <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a>. (See <a href=\"#H4\" class=\"local\">'Hepatic vascular injury'</a> above.)</p><p><a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">Capecitabine</a> is a fluoropyrimidine that is absorbed through the intestinal wall and then metabolized to the active metabolite, FU. Capecitabine causes hyperbilirubinemia, but this is sometimes attributable to hemolysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/78-80\" class=\"abstract_t\">78-80</a>].</p><p>Because of the liver's role in the catabolism of intravenous FU, some clinicians recommend that doses be omitted in patients with liver failure (serum bilirubin &gt;5 <span class=\"nowrap\">mg/dL)</span> (<a href=\"image.htm?imageKey=ONC%2F69104\" class=\"graphic graphic_table graphicRef69104 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47\" class=\"abstract_t\">47</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information. In contrast, the pharmacology of <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> is not significantly affected by liver dysfunction, and dose reduction is not recommended [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/81\" class=\"abstract_t\">81</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Floxuridine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The FU metabolite <a href=\"topic.htm?path=floxuridine-drug-information\" class=\"drug drug_general\">floxuridine</a> (fluorodeoxyuridine [FUdR]) is administered via the hepatic artery, usually for patients with isolated liver metastases from colorectal carcinoma. (See <a href=\"topic.htm?path=nonsurgical-local-treatment-strategies-for-colorectal-cancer-liver-metastases#H11\" class=\"medical medical_review\">&quot;Nonsurgical local treatment strategies for colorectal cancer liver metastases&quot;, section on 'Hepatic intraarterial chemotherapy'</a>.)</p><p>Intraarterial FUdR is associated with significant dose-limiting liver toxicity. Hepatic damage can be manifested in two ways [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/82-84\" class=\"abstract_t\">82-84</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatocellular injury with increased <span class=\"nowrap\">AST/alanine</span> aminotransferase (ALT), alkaline phosphatase, and serum bilirubin (hepatitis pattern).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Biliary sclerosis, which results either from toxic effects on the biliary system or ischemic changes secondary to fibrosis of the pericholangitic venous plexus, both of which can result in stricture of the bile ducts [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/85-90\" class=\"abstract_t\">85-90</a>]. The incidence ranges from 1 to 26 percent. Stricture of the intrahepatic or extrahepatic bile ducts is accompanied by elevated alkaline phosphatase and serum bilirubin.</p><p/><p>FUdR-related hepatotoxicity appears to be both time and dose dependent. With rare exception, the hepatitis pattern improves with the temporary cessation of chemotherapy; however, secondary biliary sclerosis is irreversible (although treatable with stenting or dilatation) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/91,92\" class=\"abstract_t\">91,92</a>]. Two patterns of sclerosis may be evident: a diffuse pattern or a diffuse pattern with short segments of tight stricture, which are usually located in the proximal bile ducts.</p><p>LFTs should be checked at least weekly during therapy with intrahepatic arterial FUdR and drug administration discontinued (ie, the pump emptied) when hepatic toxicity becomes evident. Treatment should be restarted only when toxicity has resolved. Dose adjustment guidelines for FUdR in this setting have been published (<a href=\"image.htm?imageKey=ONC%2F67680\" class=\"graphic graphic_table graphicRef67680 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/93\" class=\"abstract_t\">93</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Gemcitabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">Gemcitabine</a> is commonly associated with a transient rise in serum aminotransferases [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/94\" class=\"abstract_t\">94</a>], but these are seldom of clinical significance; liver failure and death are very rare. There are case reports of rare fatal cholestatic hepatotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/95\" class=\"abstract_t\">95</a>].</p><p>There are limited and conflicting data about <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> dosing in patients with preexisting liver dysfunction:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective study of 18 patients with preexisting liver dysfunction who were enrolled into a phase I trial of escalating <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> doses, giving gemcitabine to patients with preexisting hyperbilirubinemia (bilirubin levels &gt;1.6 <span class=\"nowrap\">mg/dL)</span> led to further deterioration in liver function [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/96\" class=\"abstract_t\">96</a>]. The authors recommended an empiric initial dose reduction to 800 rather than 1000 <span class=\"nowrap\">mg/m<sup>2</sup></span> in this setting.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On the other hand, a case series of seven patients who received at least one dose of <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> (1000 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> when their serum bilirubin level was &ge;4.5 <span class=\"nowrap\">mg/dL</span> suggests that the full dose of gemcitabine can be given safely in patients with severe hepatic dysfunction [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/97\" class=\"abstract_t\">97</a>]. Only one patient had a platelet count below 100,000 <span class=\"nowrap\">cells/microL</span> that warranted reduction or withholding of a dose, and no patient had a further deterioration of liver function.</p><p/><p>Specific dosing guidelines for patients with hepatic insufficiency are not provided in the United States prescribing information. However, it is probably prudent to utilize at least a 20 percent dose reduction for patients with hyperbilirubinemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/98\" class=\"abstract_t\">98</a>]. In the absence of toxicity, dose re-escalation could be considered.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h3\">Mercaptopurine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatotoxicity related to the purine analog 6-mercaptopurine (6-MP) is most common if the usual daily dose of 2 <span class=\"nowrap\">mg/kg</span> is exceeded. Two patterns have been noted: cholestatic liver damage and hepatocellular injury [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/99-103\" class=\"abstract_t\">99-103</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with cholestasis, histologic features include bland cholestasis, with minimal hepatic necrosis but significant cytologic atypia and disorganized hepatic cords [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/102,103\" class=\"abstract_t\">102,103</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatocellular injury typically occurs more than 30 days after treatment initiation. Moderate elevations in serum transaminases and alkaline phosphatase are accompanied by serum bilirubin levels between 3 and 7 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/100\" class=\"abstract_t\">100</a>].</p><p/><p>Changing the route of administration from oral to intravenous does not alter the pattern of hepatotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/104\" class=\"abstract_t\">104</a>]. Spontaneous resolution generally follows drug discontinuation.</p><p>Hepatotoxicity is thought to be a direct toxic effect of 6-MP because rechallenge does not necessarily shorten the latent period, and systemic manifestations of hypersensitivity (eg, rash, arthralgias, and eosinophilia) are usually not present [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/100\" class=\"abstract_t\">100</a>]. However, in a series of 396 patients treated with 6-MP (1.5 <span class=\"nowrap\">mg/kg</span> per day for an average of 60 months) for refractory inflammatory bowel disease, hepatitis developed in only one, and liver biopsy suggested a hypersensitivity reaction [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/105\" class=\"abstract_t\">105</a>]. Hepatotoxicity has been described in patients treated with the combination of standard dose 6-MP and <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>. (See <a href=\"#H55\" class=\"local\">'Combination chemotherapy regimens'</a> below.)</p><p>6-MP is metabolized in the liver by xanthine oxidase. Although specific guidelines are not available, dose reduction should be considered in patients with severe liver dysfunction to prevent drug accumulation.</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h3\">Azathioprine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AZ, a nitroimidazole derivative of 6-MP, is used as an immunosuppressive agent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/106\" class=\"abstract_t\">106</a>].</p><p>Hepatotoxicity is less frequent, milder, and less dose-dependent compared with 6-MP. Three different patterns of hepatotoxicity have been reported: hypersensitivity, an idiosyncratic cholestatic reaction, and presumed endothelial cell injury, with raised portal pressures, SOS, or peliosis hepatis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/107\" class=\"abstract_t\">107</a>]. Most reports of SOS have been observed in the setting of renal or hepatic transplantation. (See <a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">&quot;Drug-induced liver injury&quot;</a> and <a href=\"#H4\" class=\"local\">'Hepatic vascular injury'</a> above.)</p><p>Cholestatic injury is characterized by an increased serum bilirubin and alkaline phosphatase, with moderate elevations in <span class=\"nowrap\">AST/ALT,</span> and by variable degrees of parenchymal cell necrosis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/107-109\" class=\"abstract_t\">107-109</a>]. It is speculated that patients who develop hepatotoxicity convert AZ into 6-MP at an unusually rapid rate [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/110\" class=\"abstract_t\">110</a>], an example of genetically-determined host metabolic idiosyncrasy.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h3\">Thioguanine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>6-thioguanine (6-TG) has been implicated in the development of hepatic SOS [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/14,111-113\" class=\"abstract_t\">14,111-113</a>] and in a single case of peliosis hepatis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/114\" class=\"abstract_t\">114</a>]. An early report described jaundice among the potential adverse reactions [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/115\" class=\"abstract_t\">115</a>]. 6-TG is rapidly and extensively metabolized in the liver. Thus, dose reduction or avoidance is recommended in patients with hepatic disease, although formal guidelines are lacking. (See <a href=\"#H4\" class=\"local\">'Hepatic vascular injury'</a> above.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h3\">Methotrexate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a> (MTX) is a frequent component of combination chemotherapy regimens and is also used to treat a variety of nonmalignant disorders.</p><p>MTX-induced hepatotoxicity in patients receiving the drug parenterally for treatment of cancer usually takes the form of an acute transaminitis. This is most common in patients receiving high-dose MTX, which causes acute transaminitis in as many as 60 to 80 percent of patients; levels typically return to baseline within one to two weeks. (See <a href=\"topic.htm?path=therapeutic-use-and-toxicity-of-high-dose-methotrexate#H11\" class=\"medical medical_review\">&quot;Therapeutic use and toxicity of high-dose methotrexate&quot;, section on 'Hepatotoxicity'</a>.)</p><p>In contrast, patients undergoing chronic low-dose MTX therapy for rheumatoid arthritis or psoriasis are at risk for cirrhosis and fibrosis. This topic is discussed separately. (See <a href=\"topic.htm?path=hepatotoxicity-associated-with-chronic-low-dose-methotrexate-for-nonmalignant-disease\" class=\"medical medical_review\">&quot;Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease&quot;</a>.)</p><p>There are at least three case reports of hepatocellular carcinoma developing in patients with MTX-induced hepatic fibrosis, all of which were in children treated for acute lymphocytic leukemia (ALL), one in a patient heterozygous for alpha-1 antitrypsin deficiency [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/116-118\" class=\"abstract_t\">116-118</a>]. These data suggest a potential for long-term carcinogenesis following treatment with MTX, at least in the rare patient who develops hepatic fibrosis. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;</a>.)</p><p>In low doses, MTX is excreted mainly unchanged in the urine, while in high doses (such as are used to treat osteosarcoma and central nervous system [CNS] lymphoma), it is partially metabolized by the liver to 7-hydroxymethotrexate [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/119\" class=\"abstract_t\">119</a>]. Specific dosing guidelines for hepatic insufficiency are not available in the United States prescribing information. Some clinicians suggest a 25 percent dose reduction for patients with either serum bilirubin 3.1 to 5 <span class=\"nowrap\">mg/dL</span> or aminotransferases &gt;3 times the ULN, and omission of the drug for higher bilirubin levels [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47\" class=\"abstract_t\">47</a>].</p><p>Any third-space fluid (eg, ascites, pleural effusions) will accumulate MTX and act as a reservoir for slow distribution into the plasma, increasing the risk of toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/120\" class=\"abstract_t\">120</a>]. Large pleural or peritoneal effusions should be drained prior to therapy (particularly with high-dose MTX), and if this not possible, dose reduction is appropriate. (See <a href=\"topic.htm?path=therapeutic-use-and-toxicity-of-high-dose-methotrexate\" class=\"medical medical_review\">&quot;Therapeutic use and toxicity of high-dose methotrexate&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10245190\"><span class=\"h3\">Pemetrexed and pralatrexate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">Pemetrexed</a> and <a href=\"topic.htm?path=pralatrexate-drug-information\" class=\"drug drug_general\">pralatrexate</a> are novel folate analogs used in the treatment of lung cancer and refractory T-cell lymphomas, respectively. There are no published guidelines to guide dose reductions for patients with preexisting hepatic dysfunction. However, both drugs are potentially hepatotoxic, and guidelines for dose reduction for patients who develop grade 3 or 4 treatment-related hepatotoxicity during treatment are available in the United States prescribing information:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a>, reduce dose by 75 percent for bilirubin elevation &gt;3 X ULN or transaminase elevation &gt;5 X ULN.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For <a href=\"topic.htm?path=pralatrexate-drug-information\" class=\"drug drug_general\">pralatrexate</a>, if total bilirubin &gt;3 to 10 X ULN, or transaminases &gt;5 to 20 X ULN, omit dose; after recovery to &le;grade 2 toxicity, decrease dose to 20 <span class=\"nowrap\">mg/m<sup>2</sup></span>. For bilirubin &gt;10 X ULN or transaminases &gt;20 X ULN, discontinue treatment.</p><p/><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">Antitumor antibiotics</span></p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h3\">Anthracyclines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The anthracyclines include <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> (free and liposome-encapsulated), <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> (free and liposome-encapsulated), <a href=\"topic.htm?path=epirubicin-drug-information\" class=\"drug drug_general\">epirubicin</a>, and <a href=\"topic.htm?path=idarubicin-drug-information\" class=\"drug drug_general\">idarubicin</a>. Doxorubicin is the most widely studied of these agents; the other compounds appear to be metabolized similarly and have a comparable pattern of toxicity.</p><p>Isolated case reports have suggested that <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> can cause increased aminotransferases and hyperbilirubinemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/121\" class=\"abstract_t\">121</a>]. However, these have generally been in the context of acute leukemia, where multiple factors may have contributed to hepatic dysfunction, or in patients undergoing right upper quadrant irradiation. (See <a href=\"#H5\" class=\"local\">'Irradiation plus chemotherapy'</a> above.)</p><p><a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">Doxorubicin</a> is extensively metabolized in the liver; approximately 80 percent of each dose is excreted in bile. Patients with cholestasis have delayed clearance of doxorubicin and its metabolites and greater systemic toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/122-124\" class=\"abstract_t\">122-124</a>]. In contrast, patients with cirrhosis or isolated aminotransferase elevation may have normal drug clearance; excess toxicity has been reported from standard doses in some [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/125,126\" class=\"abstract_t\">125,126</a>], but not all [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/127\" class=\"abstract_t\">127</a>], studies.</p><p>Approaches to <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> dosing in patients with impaired liver function are variable (<a href=\"image.htm?imageKey=ONC%2F69104\" class=\"graphic graphic_table graphicRef69104 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47,76,127-129\" class=\"abstract_t\">47,76,127-129</a>]. The United States prescribing information for doxorubicin and liposomal doxorubicin recommend a 50 percent dose reduction for bilirubin 1.2 to 3 <span class=\"nowrap\">mg/dL,</span> and a 75 percent dose reduction for bilirubin 3.1 to 5 <span class=\"nowrap\">mg/dL</span>. Others suggest omission of the drug for bilirubin &gt;5 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47,98\" class=\"abstract_t\">47,98</a>].</p><p>The applicability of these guidelines to weekly schedules of <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> administration is uncertain. In one report, weekly administration was well tolerated in a woman with hepatic metastases from breast cancer and hyperbilirubinemia; treatment led to symptomatic improvement and normalization of LFTs [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/130\" class=\"abstract_t\">130</a>].</p><p>The United States prescribing information for <a href=\"topic.htm?path=epirubicin-drug-information\" class=\"drug drug_general\">epirubicin</a>, <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a>, and liposome-encapsulated daunorubicin also recommends dose reduction for patients with serum bilirubin levels &ge;1.2 <span class=\"nowrap\">mg/dL,</span> and for epirubicin, a dose reduction for aminotransferase levels &gt;2 X ULN (<a href=\"image.htm?imageKey=ONC%2F69104\" class=\"graphic graphic_table graphicRef69104 \">table 2</a>). Others have suggested dose modification for epirubicin based upon serum AST and the desired drug exposure level, but measurement of drug levels is not a common practice [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/131\" class=\"abstract_t\">131</a>].</p><p>Specific recommendations are not available for <a href=\"topic.htm?path=idarubicin-drug-information\" class=\"drug drug_general\">idarubicin</a>, although the United States prescribing information suggests that a dose reduction be considered in patients with hepatic impairment.</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h3\">Mitoxantrone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">Mitoxantrone</a> is an anthraquinone that is structurally related to the anthracyclines. In patients with leukemia, transient elevations in aminotransferase levels have been reported [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/132,133\" class=\"abstract_t\">132,133</a>].</p><p>Total body drug clearance is reduced in patients with altered liver function, particularly hyperbilirubinemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/134-136\" class=\"abstract_t\">134-136</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information. Some clinicians recommend maintaining a standard dose of 14 <span class=\"nowrap\">mg/m<sup>2</sup></span> for moderate dysfunction (bilirubin 1.5 to 3.5 <span class=\"nowrap\">mg/dL)</span> and reducing the dose to 8 <span class=\"nowrap\">mg/m<sup>2</span> </sup>or avoidance of <a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">mitoxantrone</a> for those with severe hepatic impairment and a bilirubin level &gt;3.5 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/134\" class=\"abstract_t\">134</a>].</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h3\">Bleomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately one-half of each administered dose of <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a> is excreted unchanged in the urine; the remainder is inactivated by an aminopeptidase that is present in many tissues, including liver. Most studies report a low incidence of liver dysfunction in patients receiving bleomycin [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/137,138\" class=\"abstract_t\">137,138</a>]. One review of over 1000 treated patients concluded that hepatotoxicity was inconsistently reported, and no specific pattern could be ascribed to this drug [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/137\" class=\"abstract_t\">137</a>].</p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h3\">Mitomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although hepatotoxicity is rare in patients treated with <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a>, drug-induced alterations in LFTs [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/139\" class=\"abstract_t\">139</a>] and hepatic SOS in the setting of high-dose therapy with hematopoietic cell transplantation [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/140\" class=\"abstract_t\">140</a>] have been reported.</p><p><a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">Mitomycin</a> is metabolized predominantly in the liver; less than 10 percent is excreted unchanged in the urine, and biliary excretion also accounts for some elimination [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/141\" class=\"abstract_t\">141</a>]. However, there are conflicting data regarding the influence of hepatic function on mitomycin clearance. In one report of 30 patients treated with mitomycin, there was no relationship between abnormal liver function, elimination half-life, and total body clearance [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/142\" class=\"abstract_t\">142</a>]. Others have documented increased myelotoxicity in patients with preexisting hepatic dysfunction [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/143\" class=\"abstract_t\">143</a>].</p><p>Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information. A number of different approaches have been utilized in patients with neoplasia-related hepatic dysfunction:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of women with advanced breast cancer and a predominance of visceral disease, initial <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a> doses were empirically adjusted for liver dysfunction as follows: bilirubin 1.5 to 3 <span class=\"nowrap\">mg/dL,</span> 50 percent of dose; bilirubin &gt;3.1 <span class=\"nowrap\">mg/dL,</span> 25 percent of dose [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/144\" class=\"abstract_t\">144</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a second report, the dose of <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a> was empirically decreased by 50 percent in patients with a serum bilirubin &gt;3 <span class=\"nowrap\">mg/dL</span> or hepatic enzymes &gt;3 X ULN [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/145\" class=\"abstract_t\">145</a>].</p><p/><p class=\"headingAnchor\" id=\"H31\"><span class=\"h3\">Dactinomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dactinomycin-drug-information\" class=\"drug drug_general\">Dactinomycin</a> can cause a transient elevation in aminotransferases, which has most commonly occurred in children who received prior radiation therapy to the right upper quadrant. In this setting, greater than anticipated leukopenia and thrombocytopenia have also occurred, suggesting prolonged drug excretion due to radiation-induced hepatotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/146\" class=\"abstract_t\">146</a>]. (See <a href=\"#H5\" class=\"local\">'Irradiation plus chemotherapy'</a> above.)</p><p>Hepatotoxicity also occurs in unirradiated patients receiving <a href=\"topic.htm?path=dactinomycin-drug-information\" class=\"drug drug_general\">dactinomycin</a> and appears to be schedule dependent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/147,148\" class=\"abstract_t\">147,148</a>]. In one series of patients with Wilms tumor receiving dactinomycin either on five consecutive days or a double dose on a single day, hepatotoxicity developed in 13 versus 0 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/147\" class=\"abstract_t\">147</a>].</p><p>A hepatopathy-thrombocytopenia syndrome (HTS) has been described in approximately 1 percent of children treated with <a href=\"topic.htm?path=dactinomycin-drug-information\" class=\"drug drug_general\">dactinomycin</a> for Wilms tumor [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/11\" class=\"abstract_t\">11</a>]. Hepatic veno-occlusive disease (VOD) is also reported. (See <a href=\"#H4\" class=\"local\">'Hepatic vascular injury'</a> above.)</p><p>Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information. A 50 percent reduction of dose has been recommended by some clinicians (<a href=\"image.htm?imageKey=ONC%2F69104\" class=\"graphic graphic_table graphicRef69104 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47\" class=\"abstract_t\">47</a>].</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h3\">Dacarbazine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There have been several reports of hepatic vascular toxicity in adults with melanoma who received single agent <a href=\"topic.htm?path=dacarbazine-drug-information\" class=\"drug drug_general\">dacarbazine</a> (DTIC). Clinical findings include acute hepatic failure, shock, and death within a few days [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/149\" class=\"abstract_t\">149</a>]. Histologically, acute thrombotic occlusions are present involving the small and medium-sized veins, unlike classic nonthrombotic SOS. Eosinophilia and eosinophilic infiltrates are frequently present, suggesting an idiosyncratic hypersensitivity mechanism rather than direct endoluminal damage [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/5,149\" class=\"abstract_t\">5,149</a>]. (See <a href=\"#H4\" class=\"local\">'Hepatic vascular injury'</a> above.)</p><p>DTIC is metabolized by the hepatic microsomal pathway. Although patients with abnormal liver function may be at increased risk for hematologic toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/76\" class=\"abstract_t\">76</a>], standard guidelines are not available for dose reduction in this setting.</p><p class=\"headingAnchor\" id=\"H33\"><span class=\"h2\">Tubulin-acting agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cytotoxic drugs that act upon tubulin and microtubules require dose reduction in the setting of hepatic dysfunction.</p><p class=\"headingAnchor\" id=\"H34\"><span class=\"h3\">Vinca alkaloids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Transient abnormalities in LFTs have been seen following treatment with both <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/150\" class=\"abstract_t\">150</a>] and <a href=\"topic.htm?path=vinorelbine-drug-information\" class=\"drug drug_general\">vinorelbine</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/151\" class=\"abstract_t\">151</a>]. More severe hepatotoxicity is reported in patients who received vincristine plus concurrent irradiation. (See <a href=\"#H5\" class=\"local\">'Irradiation plus chemotherapy'</a> above.)</p><p>The vinca alkaloids are metabolized primarily by the liver, and the bile is the main route of excretion. Liver dysfunction that is severe enough to raise the serum alkaline phosphatase and alter biliary excretion results in delayed clearance of <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> and <a href=\"topic.htm?path=vinblastine-drug-information\" class=\"drug drug_general\">vinblastine</a> with a greater potential for toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47,76,152,153\" class=\"abstract_t\">47,76,152,153</a>].</p><p>The United States prescribing information recommends that the dose of either agent be reduced by 50 percent in patients with a serum bilirubin &gt;3 <span class=\"nowrap\">mg/dL</span>. Other guidelines for dosing adjustments have been recommended by some clinicians [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47,98\" class=\"abstract_t\">47,98</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum bilirubin 1.5 to 3 <span class=\"nowrap\">mg/dL</span> or aminotransferases two to three times the ULN &ndash; Administer 50 percent of normal dose</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum bilirubin &gt;3 <span class=\"nowrap\">mg/dL</span> or aminotransferases &gt;3 times the ULN &ndash; Omit dose</p><p/><p>There is less information available for <a href=\"topic.htm?path=vinorelbine-drug-information\" class=\"drug drug_general\">vinorelbine</a>. The United States prescribing information recommends a 50 percent dose reduction for patients who develop moderate liver dysfunction during therapy (total bilirubin 2.1 to 3 <span class=\"nowrap\">mg/dL),</span> and a 75 percent dose reduction for more severe hyperbilirubinemia (<a href=\"image.htm?imageKey=ONC%2F69104\" class=\"graphic graphic_table graphicRef69104 \">table 2</a>). Others suggest that dose modification may not be necessary with mild to moderate liver impairment (total bilirubin &lt;3 X ULN, transaminases &lt;2.5 X ULN) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/154,155\" class=\"abstract_t\">154,155</a>].</p><p class=\"headingAnchor\" id=\"H35\"><span class=\"h3\">Etoposide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">Etoposide</a> is not usually hepatotoxic at standard doses [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/156\" class=\"abstract_t\">156</a>], although at least one report documents severe hepatocellular injury [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/157\" class=\"abstract_t\">157</a>]. At high doses, etoposide has been associated with hyperbilirubinemia and elevated transaminases and alkaline phosphatase levels approximately three weeks after administration [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/158,159\" class=\"abstract_t\">158,159</a>]. These abnormalities cleared without sequelae over 12 weeks.</p><p><a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">Etoposide</a> is extensively (97 percent) protein bound, and 70 to 80 percent of drug is eliminated through nonrenal mechanisms, presumably liver metabolism and bile excretion. Elevated serum bilirubin levels have been correlated with decreased clearance and enhanced leukopenia in some [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/160,161\" class=\"abstract_t\">160,161</a>], but not all [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/162-164\" class=\"abstract_t\">162-164</a>], studies. Others suggest that patients with increased bilirubin have an increased exposure to unbound drug, but without a reduction in total systemic clearance of the drug, possibly because of enhanced renal clearance [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/163,165,166\" class=\"abstract_t\">163,165,166</a>].</p><p>Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information. Some clinicians recommend a 50 percent dose reduction for patients with a serum bilirubin 1.5 to 3 <span class=\"nowrap\">mg/dL</span> or AST &gt;3 X ULN [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47,98\" class=\"abstract_t\">47,98</a>], and reduction or omission of the dose for higher bilirubin levels.</p><p>Low albumin levels (&lt;3.5 <span class=\"nowrap\">g/dL)</span> are associated with an increase in the fraction of free drug, and this may lead to more pronounced hematologic toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/167,168\" class=\"abstract_t\">167,168</a>]. A dose reduction by 33 or 50 percent has been recommended for patients with a reduced serum albumin [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/98,167\" class=\"abstract_t\">98,167</a>].</p><p class=\"headingAnchor\" id=\"H36\"><span class=\"h3\">Taxanes</span></p><p class=\"headingAnchor\" id=\"H714826\"><span class=\"h4\">Paclitaxel and docetaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with normal baseline LFTs who are treated with either <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> or <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, transient elevations of alkaline phosphatase, AST, and bilirubin have been reported in approximately 5 to 20 percent of cases [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/169\" class=\"abstract_t\">169</a>]. Hepatic toxicity is not dose dependent, and prolonged exposure to taxanes is not associated with cumulative hepatic toxicity.</p><p>Both <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> and <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> undergo oxidation by the hepatic cytochrome P450 system and are excreted in the bile [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/170,171\" class=\"abstract_t\">170,171</a>]. Clinically significant interactions have been reported with other drugs that are metabolized by cytochrome P450, including inhibitors and inducers of CYP3A4 (<a href=\"image.htm?imageKey=CARD%2F76992\" class=\"graphic graphic_table graphicRef76992 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/172\" class=\"abstract_t\">172</a>].</p><p>Patients with slightly elevated alkaline phosphatase or aminotransferases have decreased <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> clearance and are at increased risk for severe treatment-related toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/173,174\" class=\"abstract_t\">173,174</a>]. The impact of hepatic dysfunction on paclitaxel clearance varies depending upon the duration of drug infusion and the extent of liver abnormalities [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/175-177\" class=\"abstract_t\">175-177</a>].</p><p>The <a href=\"http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01&amp;token=wkMsh/eM4ol6jrYVdHE5kvoKjDjCc2Qi2fAy9lQIcbZ8IOpF0UvtAs0HugtJAxXeEoSqjZfNRB4FkmLgTen1hq3Vik4u9Yj3emB170qk1AjOIlprRVaLX8RLM+0+q2PD&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends the following dose modifications for preexisting liver disease in patients receiving three-hour infusions [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/178\" class=\"abstract_t\">178</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Total bilirubin &le;1.25 the ULN <strong>and</strong> AST &lt;10 X ULN &ndash; total dose 175 <span class=\"nowrap\">mg/m<sup>2</sup></span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Total bilirubin 1.26 to 2 X ULN <strong>and</strong> aminotransferases &lt;10 X ULN &ndash; total dose 135 <span class=\"nowrap\">mg/m<sup>2</sup></span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Total bilirubin 2.01 to 5 X ULN <strong>and</strong> aminotransferases &lt;10 X ULN &ndash; total dose 90 <span class=\"nowrap\">mg/m<sup>2</sup></span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Total bilirubin &gt;5 X ULN <strong>or</strong> aminotransferases &ge;10 X ULN &ndash; not recommended</p><p/><p>None of the data used to derive these guidelines were from patients treated with <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> over one hour or with weekly therapy. It is unknown if these dose reduction schema are suitable for such patients, and further studies with a prospective design are needed.</p><p>For nanoparticle albumin-bound <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> (<a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a>, Abraxane), the <a href=\"http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4&amp;token=4xZOah05XBA0E6bQ2DLMZwcoFvtX1yY+sRBaK45IJwNZTGBrAil1ZSikTgB9pzKQ/a1u4uXuMr+FgBDyLaSdBz+QFegAkbTYAVSjPn4L850XQLdM1FwjfI6kvIz3iznf&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends reduced initial doses in patients with any malignancy who have severe hepatic impairment (AST &gt;10 X ULN OR bilirubin &gt;5 X ULN); they also recommend not administering the drug to patients with pancreatic cancer who have moderate or severe hepatic impairment (ALT &lt;10 X ULN and total bilirubin &gt;1.5 X ULN, or ALT &gt;10 X ULN).</p><p>Decreased <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> clearance occurs in patients with elevated bilirubin <span class=\"nowrap\">and/or</span> transaminase levels. In some studies, even a slight or moderate increase in pretreatment bilirubin level was associated with toxic deaths [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/179-181\" class=\"abstract_t\">179-181</a>].</p><p>Guidelines for dose reduction in the setting of hepatic dysfunction are variable:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807&amp;token=d9bwdCiOkZsXe25S1u8zPWHke2wa3/TbDzrLIAsF8uaHof6WixCXCm9LjToWJj/AW2NTzrJLwajz73GP9r3wRUWx/5ps4/xy9nY/G4+kV5CbZ+R+vkKAW3Md7vcv64/7&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> suggests that <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> not be given if the baseline serum bilirubin is above the ULN, or to patients with AST &gt;1.5 X ULN in conjunction with an alkaline phosphatase &gt;2.5 X ULN.</p><p/><p class=\"bulletIndent1\">In the specific setting of gastric cancer when <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> is administered in conjunction with <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> and FU, a 20 percent dose reduction is recommended in patients who develop aminotransferase elevation &gt;2.5 to &le;5 X ULN and alkaline phosphatase &le;2.5 X ULN, or aminotransferases &gt;1.5 to &le;5 X ULN and alkaline phosphatase &gt;2.5 to &le;5 X ULN [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/182\" class=\"abstract_t\">182</a>]. For more severe hepatic dysfunction, drug discontinuation is recommended.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Based upon pharmacokinetic modeling, others have recommended a 20 to 40 percent dose reduction for patients with grade 2 or 3 elevations in aminotransferases (&gt;2.5 to 20 X ULN, (<a href=\"image.htm?imageKey=ONC%2F77533\" class=\"graphic graphic_table graphicRef77533 \">table 1</a>)) at baseline in conjunction with elevated levels of alkaline phosphatase [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/183\" class=\"abstract_t\">183</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A dose modification scheme for weekly <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> administration based upon preexisting liver dysfunction has been proposed for Asian patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/184\" class=\"abstract_t\">184</a>].</p><p/><p>Whether <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> is contraindicated in patients with severe liver dysfunction on the basis of metastatic cancer involvement is unclear. Administration of reduced-dose docetaxel has been successful in at least one report of a patient with breast cancer metastasis-related severe liver dysfunction [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/185\" class=\"abstract_t\">185</a>].</p><p class=\"headingAnchor\" id=\"H714836\"><span class=\"h4\">Cabazitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cabazitaxel-drug-information\" class=\"drug drug_general\">Cabazitaxel</a> is a semisynthetic taxane that is approved for treatment of advanced prostate cancer. There is no published experience with cabazitaxel in patients with impaired hepatic function. However, cabazitaxel is extensively metabolized by the liver, and hepatic impairment is likely to increase exposure to the drug. The <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201023s015lbl.pdf&amp;token=N1PpxtfhHpHc7ws5sn+7+PS8XU4pqWplMxBEXEvPulmlL+KVRBvNsDQUzy7ELHZc6O9yIZk5Ldz5NA9FTvTvH55OSpx76k7Jyf+sJiYp3zQ=&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> suggests that the drug not be administered to patients with bilirubin levels more than 3 X ULN and that the starting dose be reduced in those with mild or moderate hepatic impairment (any bilirubin level above the ULN or AST &gt;1.5 X ULN).</p><p class=\"headingAnchor\" id=\"H37\"><span class=\"h3\">Ixabepilone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ixabepilone-drug-information\" class=\"drug drug_general\">Ixabepilone</a> is a microtubule inhibitor in the epothilone class that has been approved for treatment of chemotherapy resistant patients with metastatic breast cancer. (See <a href=\"topic.htm?path=systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy#H99379855\" class=\"medical medical_review\">&quot;Systemic treatment of metastatic breast cancer in women: Chemotherapy&quot;, section on 'Ixabepilone'</a>.)</p><p><a href=\"topic.htm?path=ixabepilone-drug-information\" class=\"drug drug_general\">Ixabepilone</a> is metabolized in the liver, and drug exposure is significantly increased in patients with hepatic disease [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/186\" class=\"abstract_t\">186</a>]. United States prescribing information for initial dose modification for ixabepilone monotherapy is indicated in the table (<a href=\"image.htm?imageKey=ONC%2F69104\" class=\"graphic graphic_table graphicRef69104 \">table 2</a>). Subsequent dosing should be based upon treatment tolerance. Ixabepilone monotherapy is not recommended for aminotransferases &gt;10 X ULN, or bilirubin &gt;3 X ULN. The combination of ixabepilone with <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> is contraindicated in patients with aminotransferase elevation &ge;2.5 ULN or serum bilirubin above ULN.</p><p class=\"headingAnchor\" id=\"H742022\"><span class=\"h3\">Eribulin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=eribulin-drug-information\" class=\"drug drug_general\">Eribulin</a> mesylate, a synthetic analogue of halichondrin B, a substance derived from a marine sponge, inhibits the polymerization of tubulin and microtubules. Eribulin exposure is increased in patients with mild and moderate hepatic impairment [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/187\" class=\"abstract_t\">187</a>]. Dose modification is recommended in the United States prescribing information:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Child-Pugh A disease (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>) &ndash; decrease in initial dose to 1.1 <span class=\"nowrap\">mg/m<sup>2</sup></span> </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Child-Pugh B disease &ndash; decrease initial dose to 0.7 <span class=\"nowrap\">mg/m<sup>2</sup></span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Child-Pugh C disease &ndash; do not administer</p><p/><p class=\"headingAnchor\" id=\"H38\"><span class=\"h2\">Miscellaneous agents</span></p><p class=\"headingAnchor\" id=\"H39\"><span class=\"h3\">Bortezomib and other proteasome inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=bortezomib-drug-information\" class=\"drug drug_general\">Bortezomib</a> is predominantly metabolized by the liver, and exposure is increased in patients with moderate to severe liver impairment [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/188\" class=\"abstract_t\">188</a>]. United States prescribing information suggests a reduced starting dose (0.7 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> in the first cycle for patients with a serum bilirubin &gt;1.5 X ULN, with dose escalation or further dose reduction in subsequent cycles based upon patient tolerability [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/189\" class=\"abstract_t\">189</a>]. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-multiple-myeloma#H16\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory multiple myeloma&quot;, section on 'Bortezomib'</a>.)</p><p>A reduced starting dose is also recommended for patients with moderate or severe hepatic impairment who are treated with the orally active proteasome inhibitor <a href=\"topic.htm?path=ixazomib-drug-information\" class=\"drug drug_general\">ixazomib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/190\" class=\"abstract_t\">190</a>]. In addition, periodic monitoring of hepatic enzymes during therapy with both ixazomib and <a href=\"topic.htm?path=carfilzomib-drug-information\" class=\"drug drug_general\">carfilzomib</a> is recommended, given reports of drug-induced liver injury in &lt;1 percent of treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/190,191\" class=\"abstract_t\">190,191</a>]. </p><p class=\"headingAnchor\" id=\"H40\"><span class=\"h3\">Irinotecan and liposomal irinotecan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Combinations of <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a> and FU are used in some patients with colorectal cancer prior to the resection of liver metastases. These regimens have been associated with both steatosis and hepatic vascular injury. (See <a href=\"topic.htm?path=management-of-potentially-resectable-colorectal-cancer-liver-metastases\" class=\"medical medical_review\">&quot;Management of potentially resectable colorectal cancer liver metastases&quot;</a>.)</p><p><a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf?et_cid=36866849&et_rid=907466112&linkid=http:%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f207793lbl.pdf&amp;token=BUFO9vOh75HXvHYmB6XTFkD8KntFCW8LeDP8RlWXIim0G1zcKNH07Q7femNV080JaZ3dfZ3X+KR4ItU2T6DBE5WZFmwXhsfoVTjxv6aqyTY3jmvlRu1GF+kvnKevkQyJxPD66UXFLjLrDVm1gamUF7gEUiIO1OEhSpN3fFNJo27Dy6R8SjLaWmKgfosr2T2U&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">Nanoliposome-encapsulated irinotecan</a> is approved in combination with FU plus <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> for treatment of gemcitabine-refractory metastatic pancreatic cancer. Transaminase elevations are reported in approximately 57 percent of patients but are severe in only 6 percent. (See <a href=\"topic.htm?path=chemotherapy-for-advanced-exocrine-pancreatic-cancer\" class=\"medical medical_review\">&quot;Chemotherapy for advanced exocrine pancreatic cancer&quot;</a>.)</p><p><a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">Irinotecan</a> (whether liposome-encapsulated or not) is mainly eliminated by the liver and to a minor extent by the kidneys [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/192,193\" class=\"abstract_t\">192,193</a>]. Two main metabolic pathways take place in the liver: conversion into inactive metabolites (via the CYP3A4 isoenzyme) and into the active metabolite SN-38 by carboxylesterase enzymes. Irinotecan clearance is diminished in patients with hepatic dysfunction, and exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function.</p><p>The tolerability of <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a> in patients with hepatic dysfunction (serum bilirubin &gt;2 <span class=\"nowrap\">mg/dL)</span> has not been established. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States prescribing information for either unencapsulated irinotecan or <a href=\"topic.htm?path=liposomal-irinotecan-drug-information\" class=\"drug drug_general\">liposomal irinotecan</a>. </p><p>However, some clinicians recommend a reduction of the starting dose of unencapsulated <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a> (eg, from 350 <span class=\"nowrap\">mg/m<sup>2</sup></span> to 200 <span class=\"nowrap\">mg/m<sup>2</sup></span> every three weeks) in patients with a pretreatment serum bilirubin level 1.5 to 3 X ULN to minimize the likelihood of diarrhea and neutropenia [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/98,193,194\" class=\"abstract_t\">98,193,194</a>]. Dose reduction may also be needed for patients with a serum bilirubin 1 to 1.5 <span class=\"nowrap\">mg/dL,</span> particularly with weekly administration schedules [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/195,196\" class=\"abstract_t\">195,196</a>]. The manufacturer of <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf?et_cid=36866849&et_rid=907466112&linkid=http:%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f207793lbl.pdf&amp;token=BUFO9vOh75HXvHYmB6XTFkD8KntFCW8LeDP8RlWXIim0G1zcKNH07Q7femNV080JaZ3dfZ3X+KR4ItU2T6DBE5WZFmwXhsfoVTjxv6aqyTY3jmvlRu1GF+kvnKevkQyJxPD66UXFLjLrDVm1gamUF7gEUiIO1OEhSpN3fFNJo27Dy6R8SjLaWmKgfosr2T2U&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">liposomal irinotecan</a> states only that &quot;there is no recommended dose of the drug for patients with serum bilirubin above the upper limit of normal.&quot;</p><p>Patients with elevated aminotransferases do not appear to be more sensitive to <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a>, and dose reduction is probably not needed [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/194\" class=\"abstract_t\">194</a>]. However, the available data are insufficient to make a specific recommendation.</p><p class=\"headingAnchor\" id=\"H41\"><span class=\"h3\">Platinum derivatives</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> is a rare cause of steatosis and cholestasis at standard doses [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/197\" class=\"abstract_t\">197</a>]. Minor transient elevations in transaminases can occur during treatment [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/198\" class=\"abstract_t\">198</a>] and are more frequent at higher doses [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/199\" class=\"abstract_t\">199</a>]. Mild reversible increases in alkaline phosphatase and serum aminotransferases have also been reported with <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> and <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a>. There is at least one report of carboplatin-induced liver failure [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/200\" class=\"abstract_t\">200</a>] and one autopsy-documented case of hepatic SOS in a patient who received high-dose carboplatin and <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a> in addition to multiple other medications [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/201\" class=\"abstract_t\">201</a>]. (See <a href=\"#H4\" class=\"local\">'Hepatic vascular injury'</a> above.)</p><p>Combinations of <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a> and FU are used in some patients with colorectal cancer prior to the resection of liver metastases. These neoadjuvant regimens have been associated with steatosis, hepatic vascular injury, and nodular regenerative hyperplasia (now termed idiopathic noncirrhotic portal hypertension [including nodular regenerative hyperplasia]). (See <a href=\"topic.htm?path=management-of-potentially-resectable-colorectal-cancer-liver-metastases\" class=\"medical medical_review\">&quot;Management of potentially resectable colorectal cancer liver metastases&quot;</a> and <a href=\"topic.htm?path=noncirrhotic-portal-hypertension#H2\" class=\"medical medical_review\">&quot;Noncirrhotic portal hypertension&quot;, section on 'Idiopathic noncirrhotic portal hypertension (including nodular regenerative hyperplasia)'</a>.)</p><p>All three drugs are predominantly renally excreted. No published studies are available to guide dosing in patients with liver dysfunction. Results from single case reports, clinical trials conducted in patients with metastatic colorectal cancer, and from a dose-escalating and pharmacologic study in patients with various tumor types indicate that <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a> can be administered without dose modification, even in patients with severe liver dysfunction [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/202-204\" class=\"abstract_t\">202-204</a>]. (See <a href=\"topic.htm?path=systemic-chemotherapy-for-metastatic-colorectal-cancer-completed-clinical-trials#H27\" class=\"medical medical_review\">&quot;Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials&quot;, section on 'Oxaliplatin'</a>.)</p><p class=\"headingAnchor\" id=\"H42\"><span class=\"h3\">Asparaginase</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatotoxicity is frequent with Escherichia coli-derived L-asparaginase (L-asp). Hepatotoxicity is characterized by moderate reversible elevation of aminotransferases, bilirubin, <span class=\"nowrap\">and/or</span> alkaline phosphatase. Hyperammonemia may develop as asparagine is broken down.</p><p>The mechanism is uncertain, but probably involves impaired protein synthesis from asparagine depletion. Liver steatosis, likely due to decreased lipoprotein synthesis, is found at autopsy in 42 to 87 percent of treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/205,206\" class=\"abstract_t\">205,206</a>]. Some series describe a lower likelihood of abnormalities of LFTs following administration of pegylated-L-asp (<a href=\"topic.htm?path=pegaspargase-drug-information\" class=\"drug drug_general\">Pegaspargase</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/207\" class=\"abstract_t\">207</a>], but others describe a high frequency of grade 3 or 4 transaminitis (63 percent) and hyperbilirubinemia (31 percent) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/208\" class=\"abstract_t\">208</a>]. Recovery may be prolonged.</p><p>Systemic clearance of L-asp is not dependent on renal or liver function. As a result, dose modifications are not usually required.</p><p class=\"headingAnchor\" id=\"H43\"><span class=\"h3\">Procarbazine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatotoxicity appears to be uncommon with <a href=\"topic.htm?path=procarbazine-drug-information\" class=\"drug drug_general\">procarbazine</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/209\" class=\"abstract_t\">209</a>]. The drug has been implicated as a cause of granulomatous hepatitis [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/210\" class=\"abstract_t\">210</a>].</p><p>Following oral administration, most <a href=\"topic.htm?path=procarbazine-drug-information\" class=\"drug drug_general\">procarbazine</a> is rapidly converted to azo-procarbazine by erythrocyte and hepatic microsomal enzymes. Further metabolism has not been clearly defined. Although dose modification in patients with hepatic dysfunction is probably advisable, no formal guidelines have been published.</p><p class=\"headingAnchor\" id=\"H1507796661\"><span class=\"h3\">Lenalidomide and pomalidomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">Lenalidomide</a> and <a href=\"topic.htm?path=pomalidomide-drug-information\" class=\"drug drug_general\">pomalidomide</a> are <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> analogs that are approved for treatment of multiple myeloma. Potentially fatal hepatotoxicity is reported with both drugs, and liver function tests should be monitored periodically during therapy. </p><p>Because <a href=\"topic.htm?path=pomalidomide-drug-information\" class=\"drug drug_general\">pomalidomide</a> is metabolized primarily by the liver, dose adjustment is recommended for mild or moderate (Child-Pugh A or B (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>); 25 percent dose reduction), and severe (Child-Pugh C; 50 percent dose reduction) hepatic impairment. On the other hand, the elimination of <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> is predominantly by the renal route, and the United States prescribing information does not specify the need for dose reduction in those with hepatic insufficiency.</p><p class=\"headingAnchor\" id=\"H44\"><span class=\"h3\">Hydroxyurea</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">Hydroxyurea</a> has been rarely reported to produce liver toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/211-213\" class=\"abstract_t\">211-213</a>]. One case report describes hydroxyurea-induced hypersensitivity hepatitis with recurrence upon rechallenge [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/212\" class=\"abstract_t\">212</a>].</p><p><a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">Hydroxyurea</a> is well absorbed from the gastrointestinal tract, and 50 percent of the drug is excreted unchanged in the urine. There are no published guidelines for dose reduction in patients with liver dysfunction.</p><p class=\"headingAnchor\" id=\"H627314962\"><span class=\"h3\">Arsenic trioxide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>On the basis of limited data from patients receiving <a href=\"topic.htm?path=arsenic-trioxide-drug-information\" class=\"drug drug_general\">arsenic trioxide</a> for hepatocellular cancer, there appears to be no clear trend toward an increase in systemic exposure to the pharmacologically active metabolites of arsenic trioxide with decreasing levels of hepatic function [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/214\" class=\"abstract_t\">214</a>]. Nevertheless, given the limited amount of available data, caution is advised in the use of the drug in patients with hepatic impairment, and patients with severe hepatic impairment (eg, Child-Pugh C cirrhosis (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>)) should be closely monitored for toxicity.</p><p class=\"headingAnchor\" id=\"H459304121\"><span class=\"h3\">Vorinostat, belinostat, and panobinostat</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vorinostat-drug-information\" class=\"drug drug_general\">Vorinostat</a> is an inhibitor of histone deacetylase enzymes; it is used only for treatment of cutaneous T-cell lymphoma. Patients with varying degrees of hepatic dysfunction require dose reduction even though vorinostat pharmacokinetics are unaltered [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/215\" class=\"abstract_t\">215</a>].</p><p>United States prescribing information recommends reduced doses for patients with mild to moderate hepatic impairment (total bilirubin &gt;1 to 3 X ULN) and that the drug be avoided in those with severe impairment (total bilirubin &gt;3 X ULN). Canadian guidelines recommend avoidance of the drug for all patients with total bilirubin &ge;1.5 X ULN.</p><p><a href=\"topic.htm?path=belinostat-drug-information\" class=\"drug drug_general\">Belinostat</a> is another histone deacetylase inhibitor that is approved for treatment of peripheral T-cell lymphoma. Belinostat can cause potentially fatal hepatotoxicity (there was one fatality from hepatic failure in 129 treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/216\" class=\"abstract_t\">216</a>]). LFTs should be checked before treatment and before the start of each cycle; dose reduction is recommended for any grade 3 or worse toxicity (<a href=\"image.htm?imageKey=ONC%2F77533\" class=\"graphic graphic_table graphicRef77533 \">table 1</a>).</p><p><a href=\"topic.htm?path=belinostat-drug-information\" class=\"drug drug_general\">Belinostat</a> is metabolized in the liver, and hepatic impairment is likely to increase drug exposure. Patients with moderate to severe hepatic impairment were excluded from clinical trials, and there are insufficient data to recommend a belinostat dose in these patients.</p><p><a href=\"topic.htm?path=panobinostat-drug-information\" class=\"drug drug_general\">Panobinostat</a> is a third histone deacetylase inhibitor that is approved for treatment of refractory multiple myeloma. Hepatic dysfunction, primarily elevations in serum transaminases and total bilirubin, occur and liver function should be monitored prior to and during treatment. Panobinostat is extensively metabolized in liver, and the <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf?et_cid=35529885&et_rid=907466112&linkid=http:%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f205353s000lbl.pdf&amp;token=Ulxj6m/EAtbCI8xcUXbqcCaqpsDU1W0XN3oLJj6ye73gdV2UAAZRsCXZHbyA1lpVCSo4Mtgk6ExUbux9v809ElJi0K8IumyAdY0w2aw9oAVoD5iNjinWceQm9XppAb+jlG3wtJlOOf3pE7dVJj+IywKK9vD+hAhAb+WLRjL0Efbo1Q2Z8jL8WCaIN6tLZVen&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends reduced starting doses for those with mild or moderate hepatic impairment (bilirubin &le;1.0 X ULN and AST &gt;1 X ULN, or bilirubin &gt;1 to 3.0 X ULN and any AST), and avoidance of the drug for more severe hepatic impairment.</p><p class=\"headingAnchor\" id=\"H605323938\"><span class=\"h3\">Trabectedin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=trabectedin-drug-information\" class=\"drug drug_general\">Trabectedin</a> (ecteinascidin, ET-743), which is now synthesized, was originally isolated from the Caribbean sea sponge <em>Ecteinascidia turbinata</em>; it kills cells by poisoning the DNA nucleotide excision repair machinery and is an active agent for advanced STS. (See <a href=\"topic.htm?path=systemic-treatment-of-metastatic-soft-tissue-sarcoma#H23\" class=\"medical medical_review\">&quot;Systemic treatment of metastatic soft tissue sarcoma&quot;, section on 'Trabectedin'</a>.)</p><p>Severe hepatotoxicity, including hepatic failure, can occur in patients treated with <a href=\"topic.htm?path=trabectedin-drug-information\" class=\"drug drug_general\">trabectedin</a>. In one trial, the incidence of grade 3 or 4 elevations in ASL, AST, total bilirubin, or alkaline phosphatase was 35 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/217\" class=\"abstract_t\">217</a>], despite pretreatment with high-dose <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, which is recommended prior to each dose of the drug and has been shown to mitigate severe hepatotoxicity with this agent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/218\" class=\"abstract_t\">218</a>]. </p><p>LFTs should be assessed prior to each dose of <a href=\"topic.htm?path=trabectedin-drug-information\" class=\"drug drug_general\">trabectedin</a>. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=472bd78e-be17-4b9d-90f4-9482c3aec9ff&amp;token=FGDCJ3EnrI50N5eop5oYgYpIAg8Zwvc5FlbuuYfPHo9jz9wr5m4SuEmq4PbX16y0CuMW/lBnJ+e2kRDbuQzN+2CGVAeqf7rUgp1oN46KZkOXPQnyAoZ7AQhamQIW4Lbi&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> includes recommended dose modifications for hepatotoxicity during therapy.</p><p class=\"headingAnchor\" id=\"H45\"><span class=\"h1\">MOLECULARLY TARGETED AGENTS</span></p><p class=\"headingAnchor\" id=\"H11221439\"><span class=\"h2\">Kinase inhibitors</span></p><p class=\"headingAnchor\" id=\"H217131934\"><span class=\"h3\">Axitinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=axitinib-drug-information\" class=\"drug drug_general\">Axitinib</a> is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. Clinical trials in advanced renal cell carcinoma have demonstrated up to a 22 percent incidence of elevated aminotransferases with &lt;1 percent being grade 3 or 4. Routine monitoring of liver function studies is recommended during therapy.</p><p>Patients with Child-Pugh A liver dysfunction require no baseline dose adjustment, while those with Child-Pugh B liver dysfunction require a 50 percent dose reduction. No data are available on <a href=\"topic.htm?path=axitinib-drug-information\" class=\"drug drug_general\">axitinib</a> use in patients with Child-Pugh C liver dysfunction.</p><p class=\"headingAnchor\" id=\"H35110980\"><span class=\"h3\">Bosutinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=bosutinib-drug-information\" class=\"drug drug_general\">Bosutinib</a> is a multitargeted tyrosine kinase inhibitor that targets Bcr-Abl and the SRC family of tyrosine kinases. Clinical trials in patients with chronic myelogenous leukemia demonstrated transaminase elevation in 14 to 17 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/219\" class=\"abstract_t\">219</a>]. The United States prescribing information recommends monthly assay of transaminases for the first three months of treatment and as clinically indicated thereafter. Guidelines for dose reduction in patients with baseline liver impairment and for those who develop severe hepatotoxicity during therapy are available [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/219\" class=\"abstract_t\">219</a>].</p><p class=\"headingAnchor\" id=\"H217132037\"><span class=\"h3\">Crizotinib, ceritinib, and alectinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">Crizotinib</a>, <a href=\"topic.htm?path=ceritinib-drug-information\" class=\"drug drug_general\">ceritinib</a>, and <a href=\"topic.htm?path=alectinib-drug-information\" class=\"drug drug_general\">alectinib</a> are orally active inhibitors of the anaplastic lymphoma kinase (ALK); all are approved for treatment of advanced or metastatic non-small cell lung cancer if the tumor contains a characteristic EML4-ALK fusion oncogene. (See <a href=\"topic.htm?path=anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer\" class=\"medical medical_review\">&quot;Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">Crizotinib</a> &ndash; In phase II studies, grade 3 or 4 abnormal liver function tests (LFTs) occurred in 4 to 7 percent of patients receiving crizotinib; they were mostly reversible and asymptomatic, and did not recur with lower doses. However, treatment had to be permanently discontinued in 4 of 255 (1.6 percent) of cases.</p><p/><p class=\"bulletIndent1\">The <a href=\"http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7&amp;token=pR8HFDRFSK8EsIkz/owRXSsns/Mz6ovvKS2Ghl61lWuHTlvqRlQXpisDL+vfz3KNCT0edJm7/WUlCTT25a8t57HISUedSAQ0kYuiMDNk0nxevh+rlb2UXkKBtN5yRXvZ&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends that treatment be withheld for grade 3 or 4 aminotransferase elevation as long as serum bilirubin is &le;1.5 times the upper limit of normal (ULN); permanent discontinuation is advised for grade 2 or higher aminotransferase elevation if serum bilirubin is &gt;1.5 X ULN.</p><p/><p class=\"bulletIndent1\">Specific guidelines are not available for dosing in patients with preexisting liver dysfunction, since those with initial serum total bilirubin &gt;1.5 ULN or aminotransferases &gt;2.5 X ULN, were excluded from the clinical trials, even if the abnormalities were considered to be due to metastases. Given the extent of <a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">crizotinib</a> metabolism in the liver, hepatic impairment is likely to increase plasma crizotinib concentrations.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ceritinib-drug-information\" class=\"drug drug_general\">Ceritinib</a> &ndash; Drug-induced hepatotoxicity is more common in patients treated with ceritinib. In one study, elevations in alanine aminotransferase (ALT) occurred in 80 percent of 255 treated patients, and levels were greater than five times the ULN (grade &ge;3) in 27 percent; in contrast, 15 percent had elevated bilirubin levels, only 1 percent were severe [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/220\" class=\"abstract_t\">220</a>]. The <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf&amp;token=DQRBrKmwzM1eQcNI1ZSJiuHiqSEePHPDYn9QAiwnZA98qopngGumE8a8UJaa1mvLNaSdvtUL5EiwHtl5m+xDPyYGWgMP4YyD/0LJGbKjyjc=&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends monitoring LFTs (aspartate transaminase [AST], ALT, and serum bilirubin) at least monthly during therapy, with more frequent testing if transaminases are elevated. Specific guidelines are provided for dose adjustments in the setting of severe hepatotoxicity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=alectinib-drug-information\" class=\"drug drug_general\">Alectinib</a> &ndash; In phase II studies, grade 3 or 4 elevations in AST or ALT were reported in 3, 6, and 4.8 percent of patients treated with alectinib; grade 3 elevations in bilirubin developed in 2.8 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/221\" class=\"abstract_t\">221</a>]. The majority of cases occurred during the first two months of treatment. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb&amp;token=p69sYU1vIz42ELKpHxm1lHkKmR0Kvt63J1+5MZ/pQVrU9t4SAe0lejPKKVJAg4goQ26HMIhZYpM0hcldiggT1B8juF9KUGNlXJV1U/B2++/JdkTcedtVkojgvOUe8p2A&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">US prescribing information</a> recommends monitoring of liver function tests every two weeks during the first three months of therapy and then once monthly and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. Treatment should be temporarily withheld for grade 3 or 4 transaminase elevation with total bilirubin &le;2 times ULN or total bilirubin &gt;3 times ULN, and permanently discontinued for grade 3 or 4 transaminase elevation with total bilirubin &gt;2 times ULN.</p><p/><p class=\"headingAnchor\" id=\"H217131947\"><span class=\"h3\">Dasatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dasatinib-drug-information\" class=\"drug drug_general\">Dasatinib</a> is a tyrosine kinase inhibitor that targets Bcr-Abl, KIT, the platelet-derived growth factor receptor (PDGFR), and the SRC family of tyrosine kinases. Baseline liver dysfunction does not require dose modification. Grade 3 and 4 aminotransferase elevations are reported and typically respond to dose reduction or brief treatment interruption.</p><p class=\"headingAnchor\" id=\"H217132150\"><span class=\"h3\">Erlotinib and gefitinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">Erlotinib</a> and <a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">gefitinib</a> are small molecule inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Both are primarily metabolized in the liver by the cytochrome P450 system.</p><p>Hepatic dysfunction decreases clearance of <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/222\" class=\"abstract_t\">222</a>]. Patients with an elevated total serum bilirubin (above the institutional ULN) or Child-Pugh A, B, or C cirrhosis (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>) should be closely monitored during treatment. Hepatic failure and hepatorenal syndrome, occasionally fatal, have been reported, particularly in patients with preexisting moderate to severe hepatic impairment [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/223,224\" class=\"abstract_t\">223,224</a>] and in <span class=\"nowrap\">elderly/frail</span> patients on multiple medications [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/225\" class=\"abstract_t\">225</a>]. Even if baseline levels are normal, erlotinib should be interrupted or discontinued for total bilirubin &gt;3 X ULN, or for aminotransferase elevation &ge;5 X ULN during treatment.</p><p>Although the United States prescribing information does not provide specific guidelines, some clinicians recommend a reduced initial dose of <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a> (75 rather than 150 mg) in patients with AST &ge;3 X ULN or serum direct bilirubin 1 to 7 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/222\" class=\"abstract_t\">222</a>]. Others suggest that a reduced starting dose is not needed in those with moderate hepatic impairment (ie, Child-Pugh B cirrhosis (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>)) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/226\" class=\"abstract_t\">226</a>].</p><p><a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">Gefitinib</a> uncommonly causes increased aminotransferases [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/227\" class=\"abstract_t\">227</a>]. Compared with <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, there is less information on gefitinib in patients with liver dysfunction. A report of two cirrhotic patients with lung cancer noted no untoward effects using every other day administration [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/228\" class=\"abstract_t\">228</a>]. However, the United States prescribing information does not recommend dose reduction, even for patients with moderate to severe liver dysfunction [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/229\" class=\"abstract_t\">229</a>].</p><p class=\"headingAnchor\" id=\"H15191128\"><span class=\"h3\">Ibrutinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ibrutinib-drug-information\" class=\"drug drug_general\">Ibrutinib</a> is an orally active inhibitor of Bruton tyrosine kinase, a mediator of the B-cell receptor signaling pathway that inhibits malignant B-cell survival; it is approved as a single agent for treatment of mantle cell lymphoma. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-mantle-cell-lymphoma#H15175889\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory mantle cell lymphoma&quot;, section on 'Ibrutinib'</a>.)</p><p><a href=\"topic.htm?path=ibrutinib-drug-information\" class=\"drug drug_general\">Ibrutinib</a> is metabolized in the liver, and significant increases in exposure of ibrutinib are expected in patients with hepatic impairment. The <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf&amp;token=z3o1q79d6eliJR+qP9FvCVWWRkvaA4ugUciSnvqRbN7WEJAbD9qEA3j/JoqJwWXKpkO2b39QF8s6fomW854BPCznZ6K8cQxnl7FVV4t0VrA=&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends a reduced dose in patients with mild liver impairment (Child-Pugh A), and that use be avoided in patients with moderate to severe liver impairment (Child-Pugh B and C).</p><p class=\"headingAnchor\" id=\"H1736672377\"><span class=\"h3\">Idelalisib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=idelalisib-drug-information\" class=\"drug drug_general\">Idelalisib</a> is an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta; it is approved for treatment of relapsed chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma. Serious and potentially fatal hepatotoxicity has occurred in patients treated with idelalisib, predominantly within the first 12 weeks of treatment, and affecting approximately 14 percent of treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/230\" class=\"abstract_t\">230</a>]. Abnormalities have generally been reversible with dose interruption. Close monitoring of LFTs, especially during the first three months of treatment, is recommended. Dose modification guidelines for hepatotoxicity during therapy are available in the <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf&amp;token=jO2rhuNdfNIwKxEZfow4y0UYz14L9mv/B10U3uqr2I+sSRdVZwjCKZSOrgtikaMpKNvXg+OJxm6pVJpLjbQvbO2LyQKFwezXZu2e03Qq/wI=&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a>.</p><p>Systemic exposure to <a href=\"topic.htm?path=idelalisib-drug-information\" class=\"drug drug_general\">idelalisib</a> is increased in patients with preexisting hepatic insufficiency [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/230\" class=\"abstract_t\">230</a>]; however, safety and efficacy data are not available in patients with baseline moderate to severe hepatic dysfunction, as these patients were excluded from clinical studies. Patients with baseline hepatic impairment should be closely monitored for signs of toxicity.</p><p class=\"headingAnchor\" id=\"H46\"><span class=\"h3\">Imatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">Imatinib</a> is a tyrosine kinase inhibitor targeting Bcr-Abl and KIT that is metabolized by cytochrome P450; as a result, other drugs metabolized through this pathway may increase imatinib concentrations, potentially increasing its hepatotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/231\" class=\"abstract_t\">231</a>].</p><p><a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">Imatinib</a> is hepatically metabolized, but dosing guidelines for patients with baseline moderate to severe hepatic dysfunction (bilirubin &gt;1.5 X ULN) remain undetermined and are not provided in the <a href=\"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b&amp;token=aBDpkX1HPbRt6PKSd9K5QM6azUSu1VxmQxoLTgPJBSBDl15UA8QiPu+jvjFPl44axfNRi/YPbf1HjCJPCslWMor9KFQrtloG4Kk1q/Y6gs7a1z0Z0UmKGJ2GtGEktO1q&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a>. Some have suggested that the maximal daily recommended dose in patients with mild liver dysfunction (total bilirubin &lt;1.5 X ULN, AST above the ULN) should be no more than 500 mg [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/232\" class=\"abstract_t\">232</a>].</p><p><a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">Imatinib</a> causes elevations in serum LFTs <span class=\"nowrap\">(AST/ALT,</span> alkaline phosphatase, total bilirubin) in 15 to 20 percent of patients receiving the drug, most commonly during the first 12 months of treatment [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/233-235\" class=\"abstract_t\">233-235</a>]. Hepatotoxicity can be severe, and fatal acute hepatic necrosis has been reported [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/234\" class=\"abstract_t\">234</a>]. At least one report indicates that treatment with corticosteroids led to resolution of hepatic abnormalities and permitted the resumption of therapy [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/235\" class=\"abstract_t\">235</a>]. For patients who develop hepatotoxicity during therapy (elevations of total bilirubin &gt;3 X ULN or transaminases &gt;5 X ULN), the <a href=\"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b&amp;token=aBDpkX1HPbRt6PKSd9K5QM6azUSu1VxmQxoLTgPJBSBDl15UA8QiPu+jvjFPl44axfNRi/YPbf1HjCJPCslWMor9KFQrtloG4Kk1q/Y6gs7a1z0Z0UmKGJ2GtGEktO1q&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends withholding treatment until bilirubin &lt;1.5 X ULN and transaminases &lt;2.5 X ULN, then resuming treatment with a reduced dose (eg, if current dose is 400 mg daily, reduce dose to 300 mg daily).</p><p class=\"headingAnchor\" id=\"H47\"><span class=\"h3\">Lapatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">Lapatinib</a> is a dual inhibitor of both human epidermal growth factor receptor 2 <span class=\"nowrap\">(HER2)/neu</span> (erbB-2) and the EGFR, which is also called erbB-1. Lapatinib is associated with severe, potentially fatal hepatotoxicity (mainly aminotransferase elevation). In one study of 154 patients, approximately 40 percent of patients developed hepatotoxicity of any grade, and it was severe (grade 3 or 4) in one-half of cases [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/236\" class=\"abstract_t\">236</a>].</p><p>Major histocompatibility complex (MHC) variants appear to influence the risk of liver injury with <a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">lapatinib</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/237,238\" class=\"abstract_t\">237,238</a>]. In one study, inheritance of two specific human leukocyte antigen (HLA) alleles (HLA-DRB1*07:01 and HLA-DQA1*02:01, study frequency 22 percent) had the highest levels of association with ALT elevation during lapatinib therapy (odds ratio [OR] 14, 95% CI 6-31) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/237\" class=\"abstract_t\">237</a>]. Overall, carriage of one of the high-risk alleles had a low positive predictive value. Among the lapatinib-treated patients, the risk for ALT elevation &gt;5 X ULN by 13 weeks was 7.7 percent for carriers of these high-risk HLA alleles versus 0.5 percent in noncarriers. However, the risk was cumulative over time, and by 400 days of exposure, individuals with the HLA-DRB1*07:01 allele had a 15 percent probability of having ALT &gt;3 X ULN compared with 1.1 percent for noncarriers.</p><p>Taken together, these data suggest a possible immune basis for lapatinib-induced hepatotoxicity and support a potential role for genotyping to identify those who are at highest risk. However, at present, routine genotyping for the presence of one of these high-risk alleles is not yet a standard approach for patients being considered for <a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">lapatinib</a> therapy.</p><p><a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">Lapatinib</a> is extensively metabolized in the liver. The United States prescribing information suggests dose reduction for patients with severe hepatic impairment (Child-Pugh C) who are treated with lapatinib in combination with <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a>; for lapatinib in combination with <a href=\"topic.htm?path=letrozole-drug-information\" class=\"drug drug_general\">letrozole</a>, they recommend dropping the initial lapatinib dose from 1500 to 1000 mg daily (<a href=\"image.htm?imageKey=ONC%2F81280\" class=\"graphic graphic_table graphicRef81280 \">table 6</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/239\" class=\"abstract_t\">239</a>]. LFTs should be monitored at least every four to six weeks during therapy, and the drug discontinued for severe changes in liver function <span class=\"nowrap\">(ALT/AST</span> &gt;3 X ULN, bilirubin &gt;2 X ULN).</p><p class=\"headingAnchor\" id=\"H83127096\"><span class=\"h3\">Lenvatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lenvatinib-drug-information\" class=\"drug drug_general\">Lenvatinib</a> is a multitargeted tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, as well as fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; PDGFR alpha; KIT; and RET. In clinical trials involving patients with differentiated thyroid cancer, grade 3 or 4 aminotransferase elevation has been observed in 4 to 5 percent of treated patients. The <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf?et_cid=35470087&et_rid=907466112&linkid=http:%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f206947s000lbl.pdf&amp;token=4sfWzNaN8Fw72yf4stWXXyRZETM7McY0IKDpTbuV25+ufAjpCR7B6KbQCf9v5+IrE5VJlTR2/O/PXfpuO1CGHYJQK/ccyAi7VqF3W3VJWQKUIPtznNME+nqit5Z7P3mIbXSlZGBV45DlHCGP+ertRJQK1skhmWvIYWuzs0yVSi3bWnDJlU7w3JoUmxBNGo3k&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends monitoring liver function before initiation of the drug, every two weeks for the first two months, then at least monthly thereafter. The starting dose should be reduced in patients with preexisting severe hepatic impairment (Child-Pugh C cirrhosis (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>)).</p><p class=\"headingAnchor\" id=\"H217131983\"><span class=\"h3\">Nilotinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=nilotinib-drug-information\" class=\"drug drug_general\">Nilotinib</a> is a multitargeted tyrosine kinase inhibitor that targets Bcr-Abl, KIT, and PDFGR. Metabolism is primarily hepatic, and exposure is increased in patients with impaired hepatic function. The United States prescribing information recommends initial dose reduction in patients with even mild hepatic impairment (defined as Child-Pugh class A cirrhosis) (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>). The specified dose reductions are outlined in the table (<a href=\"image.htm?imageKey=ONC%2F81280\" class=\"graphic graphic_table graphicRef81280 \">table 6</a>).</p><p class=\"headingAnchor\" id=\"H217131874\"><span class=\"h3\">Pazopanib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">Pazopanib</a> is an oral agent that targets multiple tyrosine kinases including VEGFR, PDGFR, and KIT. In clinical trials, severe hepatotoxicity (increased aminotransferases and total bilirubin) has been seen in approximately 18 percent of patients; 2 of 977 died with both disease progression and hepatic failure [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/240\" class=\"abstract_t\">240</a>].</p><p>The United States prescribing information recommends that LFTs be monitored before initiation of treatment and at weeks 3, 5, 7, 9, 12, and 16, and then as clinically indicated. Treatment should be interrupted in the event of hepatotoxicity; permanent discontinuation is advised if ALT elevations &gt;3 X ULN occur concurrently with bilirubin elevations &gt;2 X ULN.</p><p>Genetic factors may influence susceptibility to pazopanib-related hepatotoxicity:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inheritance of certain polymorphisms in the uridine diphosphoglucuronosyltransferase 1A1 (UGT1A1) enzyme that cause Gilbert syndrome (the UGT1A1*28 allele) seem to be associated with pazopanib-induced hyperbilirubinemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/241,242\" class=\"abstract_t\">241,242</a>]. These results support the view that some instances of isolated hyperbilirubinemia in these patients represent a benign manifestation of Gilbert syndrome, and that continuation of <a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a> monotherapy is reasonable in this setting. Genetic testing for the UGT1A1*28 allele is available (the Invader UGT1A1 Molecular Assay), but most clinicians do not routinely test patients prior to therapy; instead, they follow LFTs closely as per the United States prescribing information. (See <a href=\"topic.htm?path=gilbert-syndrome-and-unconjugated-hyperbilirubinemia-due-to-bilirubin-overproduction\" class=\"medical medical_review\">&quot;Gilbert syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An association between carriage of HLA-B*57:01 and ALT elevation was also suggested in a genome-wide association study of 1188 pazopanib-treated patients with cancer from eight clinical trials [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/243\" class=\"abstract_t\">243</a>]. Given that HLA-B*57.01 functions as an immune receptor, these findings raise the possibility of an immune-mediated mechanism for pazopanib-associated hepatotoxicity in some patients. However, it is premature to conclude that pretreatment testing for HLA-B*57:01 is warranted to identify those who are at higher risk of hepatotoxicity.</p><p/><p><a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">Pazopanib</a> is metabolized by the liver, and dose reduction may be needed for patients with moderate to severe liver dysfunction. In a phase I study of 98 patients with hepatic dysfunction treated with pazopanib, the maximum tolerated dose in patients with moderate hepatic impairment (total bilirubin &gt;1.5 to 3 X ULN regardless of the ALT value) was 200 mg per day [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/244,245\" class=\"abstract_t\">244,245</a>]. United States prescribing information suggests dose reduction to 200 mg per day for total bilirubin 1.5 to 3 X ULN and that the drug not be used in patients with more severe liver impairment.</p><p class=\"headingAnchor\" id=\"H1157198779\"><span class=\"h3\">Ponatinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ponatinib-drug-information\" class=\"drug drug_general\">Ponatinib</a> targets Bcr-Abl, VEGFR, PDGFR, the fibroblast growth factor receptor (FGFR), the SRC family of kinases, KIT, RET, TIE2 and FLT3; it is approved in the United States for treatment of refractory chronic myelogenous leukemia. Ponatinib may result in elevations in ALT, AST, or both, and fatal acute liver failure has been described, sometimes within one week of starting therapy [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/246\" class=\"abstract_t\">246</a>]. LFTs should be evaluated at baseline, and at least monthly during therapy.</p><p>Hepatic elimination is the main route of excretion for <a href=\"topic.htm?path=ponatinib-drug-information\" class=\"drug drug_general\">ponatinib</a>. Patients with moderate to severe (Child-Pugh B or C) hepatic impairment are at increased risk for adverse reactions, and the drug should be avoided in such cases.</p><p class=\"headingAnchor\" id=\"H15667829\"><span class=\"h3\">Regorafenib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">Regorafenib</a> is a small molecule kinase inhibitor that targets VEGFR1, 2, and 3 in addition to RET, KIT, PDGFR alpha and beta, FGFR1 and 2, and several other membrane-bound and intracellular kinases that are involved in normal cellular function and in pathologic processes. It has been approved in the United States for treatment of metastatic colorectal cancer in patients previously treated with multiple cytotoxic and molecularly targeted therapies. (See <a href=\"topic.htm?path=systemic-chemotherapy-for-metastatic-colorectal-cancer-completed-clinical-trials#H17436553\" class=\"medical medical_review\">&quot;Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials&quot;, section on 'Regorafenib'</a>.)</p><p>Fatal drug-induced liver injury occurred in 0.3 percent of 1100 patients treated with <a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">regorafenib</a> on clinical trials [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/247\" class=\"abstract_t\">247</a>]. In the placebo-controlled CORRECT trial, fatal hepatic failure occurred in 1.6 percent of patients treated with regorafenib for metastatic colorectal cancer (versus 0.4 percent in the placebo group). Biopsy, where available, has shown hepatocyte necrosis with lymphocytic infiltration.</p><p>The manufacturer recommends baseline LFTs (ALT, AST, bilirubin) prior to initiating therapy and at least every two weeks during the first two months of treatment, and monthly thereafter. Dose adjustment is not recommended for preexisting mild to moderate hepatic impairment (Child-Pugh A or B cirrhosis), but use of the drug is not recommended in those with Child-Pugh C disease. For hepatotoxicity during treatment, the manufacturer recommends withholding dose until recovery for grade 3 AST or ALT elevations (<a href=\"image.htm?imageKey=ONC%2F77533\" class=\"graphic graphic_table graphicRef77533 \">table 1</a>) and to resume therapy at a reduced dose if potential benefit outweighs risk. <a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">Regorafenib</a> should be discontinued permanently for re-occurrence of <span class=\"nowrap\">AST/ALT</span> &gt;5 X ULN despite dose reduction, or for any <span class=\"nowrap\">AST/ALT</span> &gt;20 X ULN, or for <span class=\"nowrap\">AST/ALT&gt;3</span> X ULN plus bilirubin &gt;2 X ULN. Given the incidence of severe and potentially fatal hepatotoxicity, some clinicians initiate therapy at a lower dose and titrate to goal dose while monitoring liver function closely.</p><p class=\"headingAnchor\" id=\"H3239500615\"><span class=\"h3\">CDK 4/6 inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ribociclib-drug-information\" class=\"drug drug_general\">Ribociclib</a>, <a href=\"topic.htm?path=palbociclib-drug-information\" class=\"drug drug_general\">palbociclib</a>, and <a href=\"topic.htm?path=abemaciclib-drug-information\" class=\"drug drug_general\">abemaciclib</a> are orally active inhibitors of cyclin-dependent kinase (CDK) <span class=\"nowrap\">4/6</span> that are approved for treatment of hormone-receptor-positive metastatic breast cancer.</p><p>In clinical trials, 7 to 10 percent of patients treated with <a href=\"topic.htm?path=ribociclib-drug-information\" class=\"drug drug_general\">ribociclib</a> had grade 3 or 4 elevations in transaminases; approximately 1 percent had elevations in total bilirubin. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8&amp;token=iiNOOu08WSPGxVf+sDj+qH02wMDBK0BI2iHdDqZ8NUkvLo/eFircdzFh2Yzc1tepwFWTO1juuV+Knc8ZmPT5u8BygsFk1/cZb19S6hPmT7XUTn8V6QPtHSlzvmxbymo1&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information for ribociclib</a> recommends performing liver function tests at baseline, every two weeks for the first two cycles, at the beginning of each subsequent four cycles, and as clinically indicated thereafter; dose modification guidelines are available in the event of hepatotoxicity during therapy.</p><p><a href=\"topic.htm?path=ribociclib-drug-information\" class=\"drug drug_general\">Ribociclib</a> undergoes extensive hepatic metabolism. A reduced starting dose is recommended in patients with moderate to severe hepatic impairment (Child-Pugh <span class=\"nowrap\">B/C)</span>.</p><p><a href=\"topic.htm?path=palbociclib-drug-information\" class=\"drug drug_general\">Palbociclib</a> also undergoes extensive hepatic metabolism; the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07&amp;token=tKy7b1TjobkXdrakzm5qe2QY1KLJv+1z0JM99+F7n9dXCjtF0eTn9k5G6qeY2FaN8ZCzkMZPiFv7mlqapDyUKBOq7BIIfkCdLvoH50ofCKdyeyu5QFLNxwlBU1lYee8t&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information for palbociclib</a> recommends a reduced initial starting dose (from 125 to 75 mg daily) for individuals with severe hepatic impairment (Child-Pugh class C cirrhosis) but not for those with mild to moderate impairment. </p><p><a href=\"topic.htm?path=abemaciclib-drug-information\" class=\"drug drug_general\">Abemaciclib</a> is also associated with transient elevations in transaminases during therapy and is hepatically metabolized. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06&amp;token=Tmp3v/vA4JDzRu1B3w6Spc0rNG+sVE1IIz3PFSDg343Jaf+4W0Vmt4PxYcecm91H4gxc/TYplu0Wub1TPv79CFnzOb6Yy10y+clYi2nWCss102SVQqE6YOL6m7TWRZx+&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information for abemaciclib</a> lists specific guidelines for dose reduction during therapy based upon hepatotoxicity and also recommends a reduced starting dose in patients with preexisting severe (Child-Pugh C) hepatic impairment. </p><p class=\"headingAnchor\" id=\"H48\"><span class=\"h3\">Sorafenib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">Sorafenib</a> is a potent small molecule inhibitor of multiple tyrosine kinases, including VEGFR. Sorafenib-induced hepatitis is characterized predominantly by a hepatocellular pattern of liver damage with significant increases in transaminases that may result in hepatic failure and death. Uncommon elevations in the international normalized ratio (INR) or hyperbilirubinemia may occur [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/248,249\" class=\"abstract_t\">248,249</a>]. Some have suggested that hyperbilirubinemia correlates with high levels of systemic drug exposure and that both are linked to inheritance of a UGT1A1*28 allele, which is associated with reduced enzymatic activity and Gilbert syndrome [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/250\" class=\"abstract_t\">250</a>].</p><p>LFTs should be monitored regularly during treatment. The <a href=\"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0&amp;token=/V6c/pYEpT27aSKt5blCNbZnU2zjTveVQV7SNkLelIwUZayTPA5UHuVxDrY3zIFVs3pakRFqaFuIy2KC3dfN9qzxOWCBjYO4BD/8gaslzYc0Kh68gqPV/F+VrnOtXsRF&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a> recommends that if transaminases are &quot;significantly increased&quot; without alternative explanation, such as viral hepatitis or progressing underlying malignancy, that the drug be discontinued.</p><p>There are conflicting data on the need for dose reduction in patients with preexisting liver dysfunction:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Results from a phase I study suggest that dose reduction to 200 mg twice a day is required in patients with a bilirubin 1.5 to 3 X ULN, and that the drug cannot be tolerated with more severe hyperbilirubinemia [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/248\" class=\"abstract_t\">248</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On the other hand, at least one study in patients treated for advanced hepatocellular cancer concluded that dose reduction is not necessary in patients with mild to moderate aminotransferase elevation (&ge;1.8 X ULN).</p><p/><p>United States prescribing information for <a href=\"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0&amp;token=/V6c/pYEpT27aSKt5blCNbZnU2zjTveVQV7SNkLelIwUZayTPA5UHuVxDrY3zIFVs3pakRFqaFuIy2KC3dfN9qzxOWCBjYO4BD/8gaslzYc0Kh68gqPV/F+VrnOtXsRF&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">sorafenib</a> recommends no dose adjustment for Child-Pugh B impairment and makes no recommendation for those with Child-Pugh C cirrhosis (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>). However, they recommend that <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a> be discontinued for unexplained significant increases in transaminases during treatment. The tolerance of sorafenib in patients with liver disease is addressed elsewhere. (See <a href=\"topic.htm?path=systemic-treatment-for-advanced-hepatocellular-carcinoma#H3529276268\" class=\"medical medical_review\">&quot;Systemic treatment for advanced hepatocellular carcinoma&quot;, section on 'Safety in patients with liver disease'</a>.)</p><p class=\"headingAnchor\" id=\"H204884583\"><span class=\"h3\">Sunitinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">Sunitinib</a> is another potent small molecule inhibitor of multiple tyrosine kinases including VEGFR. Hepatotoxicity has been observed in clinical trials, which may result in liver failure (7 of 2281 patients, 0.3 percent); fatalities have been reported [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/251\" class=\"abstract_t\">251</a>]. Liver function should be monitored prior to and during treatment. The drug should be interrupted for bilirubin levels &gt;3 X ULN, <span class=\"nowrap\">AST/ALT</span> &gt;5 X ULN and not restarted until resolution.</p><p>As with <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a> and <a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a>, sunitinib-associated hyperbilirubinemia has been linked to inheritance of a UGT1A1*28 allele, which is associated with reduced enzymatic activity and Gilbert syndrome [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/242\" class=\"abstract_t\">242</a>].</p><p class=\"headingAnchor\" id=\"H104381194\"><span class=\"h3\">Vandetanib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vandetanib-drug-information\" class=\"drug drug_general\">Vandetanib</a> is another orally active inhibitor of several tyrosine kinases including RET, VEGFR and EGFR. In clinical trials involving patients with medullary thyroid cancer and lung cancer, aminotransferase elevation has been observed in over 20 percent of treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/252,253\" class=\"abstract_t\">252,253</a>]. Vandetanib is partially metabolized in the liver. The United States prescribing information recommends avoiding use of vandetanib in patients with moderate and severe hepatic impairment (Child-Pugh B or C cirrhosis (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>)), as safety and efficacy have not been established.</p><p class=\"headingAnchor\" id=\"H952085\"><span class=\"h3\">Vemurafenib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">Vemurafenib</a>, an orally administered kinase inhibitor of some mutated forms of BRAF, is approved for treatment of metastatic melanoma with a V600E BRAF mutation. (See <a href=\"topic.htm?path=molecularly-targeted-therapy-for-metastatic-melanoma#H100472992\" class=\"medical medical_review\">&quot;Molecularly targeted therapy for metastatic melanoma&quot;, section on 'Vemurafenib'</a>.)</p><p>In early clinical trials, grade 3 to 4 abnormalities in LFTs (gamma-glutamyl transpeptidase [GGT], transaminases, bilirubin) occurred in 2 to 12 percent of patients. The United States prescribing information recommends monitoring of liver enzymes and bilirubin before initiation and monthly during treatment.</p><p><a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">Vemurafenib</a> does not undergo appreciable hepatic metabolism, and adjustment to the starting dose is not needed for patients with preexisting mild to moderate liver impairment. Due to lack of data, the drug should be used with caution in patients with severe liver impairment.</p><p class=\"headingAnchor\" id=\"H1142217\"><span class=\"h3\">Cobimetinib and trametinib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cobimetinib-drug-information\" class=\"drug drug_general\">Cobimetinib</a> and <a href=\"topic.htm?path=trametinib-drug-information\" class=\"drug drug_general\">trametinib</a> are MEK inhibitors that are approved for the treatment of melanoma. While no dose adjustment is recommended for liver dysfunction, both drugs can cause hepatotoxicity, and baseline and periodic monitoring of liver function is recommended in the United States prescribing information. (See <a href=\"topic.htm?path=molecularly-targeted-therapy-for-metastatic-melanoma#H100473006\" class=\"medical medical_review\">&quot;Molecularly targeted therapy for metastatic melanoma&quot;, section on 'MEK inhibition'</a>.) </p><p class=\"headingAnchor\" id=\"H1577577405\"><span class=\"h2\">m-TOR inhibitors</span></p><p class=\"headingAnchor\" id=\"H54\"><span class=\"h3\">Everolimus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">Everolimus</a> is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Metabolism is primarily hepatic, and exposure is increased in patients with mild to moderate hepatic impairment (defined by the US Food and Drug Administration [FDA] as Child-Pugh class A or B cirrhosis (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>)). A 25 percent dose reduction is recommended for patients with Child-Pugh A cirrhosis being treated for breast cancer, renal cell cancer and pancreatic neuroendocrine tumor, and a 50 percent dose reduction for Child-Pugh B cirrhosis; for those with more severe hepatic impairment in whom the potential benefit outweighs risk, a maximum daily dose of 2.5 mg is recommended [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/254\" class=\"abstract_t\">254</a>]. There are different recommendations for patients receiving the drug for subependymal giant cell tumor [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/255\" class=\"abstract_t\">255</a>].</p><p class=\"headingAnchor\" id=\"H204884575\"><span class=\"h3\">Temsirolimus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=temsirolimus-drug-information\" class=\"drug drug_general\">Temsirolimus</a>, another mTOR inhibitor, also undergoes hepatic metabolism. The United States prescribing information recommends a dose reduction to 15 mg weekly in patients with mild hepatic impairment (bilirubin &gt;1 to 1.5 ULN or AST &gt;ULN) and that the drug not be administered to patients with serum bilirubin &gt;1.5 X ULN.</p><p class=\"headingAnchor\" id=\"H428907471\"><span class=\"h2\">Ado-trastuzumab emtansine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ado-trastuzumab-emtansine-drug-information\" class=\"drug drug_general\">Ado-trastuzumab emtansine</a> (T-DM1) is an antibody-drug conjugate that incorporates the HER2-targeted agent <a href=\"topic.htm?path=trastuzumab-including-biosimilars-of-trastuzumab-drug-information\" class=\"drug drug_general\">trastuzumab</a> with the cytotoxic microtubule inhibitor DM1. It is approved for advanced breast cancer in patients previously exposed to trastuzumab and taxanes. (See <a href=\"topic.htm?path=systemic-treatment-for-her2-positive-metastatic-breast-cancer\" class=\"medical medical_review\">&quot;Systemic treatment for HER2-positive metastatic breast cancer&quot;</a>.)</p><p>Serious hepatotoxicity has been reported, including liver failure and death, in patients treated with T-DM1. The typical pattern is a transient increase in ALT and AST; elevations in serum total bilirubin occur less commonly. Hepatic function should be assessed at baseline and prior to each dose. Dose adjustment is recommended for grade 3 or higher transaminase or bilirubin elevation (<a href=\"image.htm?imageKey=ONC%2F77533\" class=\"graphic graphic_table graphicRef77533 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/256\" class=\"abstract_t\">256</a>].</p><p>In clinical trials of T-DM1, cases of nodular regenerative hyperplasia (now termed idiopathic noncirrhotic portal hypertension [including nodular regenerative hyperplasia]) were identified from liver biopsies in three from a total of 884 treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/256\" class=\"abstract_t\">256</a>]. Idiopathic noncirrhotic portal hypertension is a rare condition whose overall incidence is unknown. The diagnosis should be considered in patients who develop otherwise unexplained portal hypertension that is confirmed by biopsy. Drug discontinuation is advised. (See <a href=\"topic.htm?path=noncirrhotic-portal-hypertension#H2\" class=\"medical medical_review\">&quot;Noncirrhotic portal hypertension&quot;, section on 'Idiopathic noncirrhotic portal hypertension (including nodular regenerative hyperplasia)'</a> and <a href=\"topic.htm?path=noncirrhotic-portal-hypertension#H4\" class=\"medical medical_review\">&quot;Noncirrhotic portal hypertension&quot;, section on 'Pathophysiology'</a>.)</p><p class=\"headingAnchor\" id=\"H1978954832\"><span class=\"h2\">Brentuximab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=brentuximab-vedotin-drug-information\" class=\"drug drug_general\">Brentuximab vedotin</a> is an immunotoxin comprised of a CD30-directed monoclonal antibody linked to the antitubulin agent monomethyl auristatin E (MMAE). It is approved for treatment of refractory Hodgkin lymphoma and anaplastic large cell lymphoma. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-classical-hodgkin-lymphoma#H3990798595\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory classical Hodgkin lymphoma&quot;, section on 'Brentuximab vedotin'</a> and <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma#H2145853771\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory peripheral T cell lymphoma&quot;, section on 'Brentuximab'</a>.)</p><p>Severe and potentially fatal hepatotoxicity has been reported with brentuximab. The risk may be increased in those with preexisting liver disease. Transaminases and serum bilirubin should be monitored during therapy.</p><p>Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment increases the likelihood of severe adverse reactions and death in patients receiving brentuximab. The United States prescribing information recommends avoidance of the drug in these patients.</p><p class=\"headingAnchor\" id=\"H3859599982\"><span class=\"h2\">Elotuzumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=elotuzumab-drug-information\" class=\"drug drug_general\">Elotuzumab</a> is an immunostimulatory monoclonal antibody directed against the SLAMF7 molecule that is present on myeloma cells; it is approved in conjunction with <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> and <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> for treatment of relapsed lymphoma. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-multiple-myeloma\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory multiple myeloma&quot;</a>.)</p><p>Elevations in liver enzymes <span class=\"nowrap\">(ALT/AST,</span> total bilirubin, alkaline phosphatase) were reported in 2.5 percent of patients treated with <a href=\"topic.htm?path=elotuzumab-drug-information\" class=\"drug drug_general\">elotuzumab</a> plus <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> and <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, as compared with 0.6 percent of those treated with chemotherapy alone [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/257\" class=\"abstract_t\">257</a>]. The <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf?et_cid=37060330&et_rid=907466112&linkid=http:%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f761035s000lbl.pdf&amp;token=KA7FPiQe68cfzRdp+NnOTMSylwLVMtcUpRsYujqfChR1rAyVbtwAkiPzXzfR4eZ8D3H/fkoNqPluZrHMvUvaQiP7teLky+aw2ibDGL2y+ekdegbCX73Wj7DkJiUx7/LnYQc4qK9FHqyEuFrXiUKKurvn6abepys84+OSsdaALncXe5TTRnee9VPug/aG5eoJ&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends periodic monitoring of liver enzymes and at least temporary discontinuation of the drug for &ge;grade 3 hepatotoxicity (<a href=\"image.htm?imageKey=ONC%2F77533\" class=\"graphic graphic_table graphicRef77533 \">table 1</a>). </p><p class=\"headingAnchor\" id=\"H236606549\"><span class=\"h2\">Gemtuzumab ozogamicin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">Gemtuzumab ozogamicin</a> is a CD33-directed antibody-drug conjugate that is indicated for the treatment of newly diagnosed CD33-positive acute myeloid leukemia in adults. Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD, also known as sinusoidal obstruction syndrome), has been reported with the use of this drug, and the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fd2bb2-1cfa-4250-feb8-d7956c794e05&amp;token=alXyow/rmpkzGYEexgprHNiwzrylUs5MNUyBgtNrBU5ATY2LjchlqrcRI609wDyvxCaRGYkVe4WDnJohATViDLh6T+fQDjS27Fx0WtYNfBI2qmaSX7AuFN/mdWXiJQtO&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends frequent monitoring for signs and symptoms of VOD during therapy, and that the drug be discontinued permanently if VOD develops.</p><p class=\"headingAnchor\" id=\"H244606019\"><span class=\"h2\">Ramucirumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ramucirumab-drug-information\" class=\"drug drug_general\">Ramucirumab</a> is a recombinant monoclonal antibody that binds to the VEGFR2, blocking receptor activation. It is approved in the United States for treatment of advanced gastric cancer. (See <a href=\"topic.htm?path=systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer#H193617120\" class=\"medical medical_review\">&quot;Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer&quot;, section on 'Ramucirumab'</a>.)</p><p>Clinical deterioration, manifested by worsening encephalopathy, ascites, or hepatorenal syndrome, has been reported among patients with Child-Pugh B or C (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 5</a>) cirrhosis who received the drug [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/258\" class=\"abstract_t\">258</a>]. <a href=\"topic.htm?path=ramucirumab-drug-information\" class=\"drug drug_general\">Ramucirumab</a> should only be used in these patients if the potential benefits are judged to outweigh the risks.</p><p class=\"headingAnchor\" id=\"H1577577467\"><span class=\"h2\">Immunotherapy</span></p><p class=\"headingAnchor\" id=\"H1577577479\"><span class=\"h3\">Interferon alfa-2b (IFN-alfa-2b)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>High-dose interferon is an approved adjuvant treatment for high-risk melanoma. High-dose interferon is associated with significant toxicity, including significant aminotransferase elevation, requiring dose adjustment and possibly treatment discontinuation. Aminotransferase elevation &gt;5 times normal requires dose interruption until resolution to grade 1. Treatment should then be resumed at a 33 percent reduced dose. A second event is managed in the same manner; a third event requires permanent discontinuation of interferon [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/259\" class=\"abstract_t\">259</a>].</p><p class=\"headingAnchor\" id=\"H89656322\"><span class=\"h3\">Pegylated interferon alfa (IFN-alfa)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>IFN-alfa is used as adjuvant chemotherapy for surgically resected high-risk melanoma and has been used for over a decade in treatment of hepatitis C (HCV). A randomized trial comparing observation to pegylated IFN-alfa-2b for adjuvant therapy of resected melanoma revealed grade 3 or 4 hepatotoxicity in 11 percent of IFN-alfa-2b treated patients compared with &lt;2 percent of the observation group [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/260\" class=\"abstract_t\">260</a>]. Another trial examining high-dose IFN-alfa-2b (15 X 10<sup>6</sup> <span class=\"nowrap\">unit/m<sup>2</sup></span> for five of seven days per week) for one month followed by randomization to observation versus continuation of IFN-alfa-2b at a reduced dose for one year revealed grade 1 and 2 hepatoxicity in a higher number of patients receiving prolonged treatment (75 versus 41 percent), but rates of grade 3 and 4 hepatotoxicity were similar (6 percent in each group) [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/261\" class=\"abstract_t\">261</a>].</p><p>Hepatotoxicity will generally subside with cessation of treatment, though experience with IFN-induced hepatotoxicity occurring during HCV treatment indicates that this may be in the form of autoimmune liver injury requiring immunosuppression to reverse [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/262\" class=\"abstract_t\">262</a>]. The United States prescribing information suggests treatment be discontinued for hepatic decompensation or severe hepatic injury (Child-Pugh B or C) during treatment.</p><p class=\"headingAnchor\" id=\"H1577577448\"><span class=\"h3\">Ipilimumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ipilimumab-drug-information\" class=\"drug drug_general\">Ipilimumab</a> is a monoclonal antibody directed against CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on the T cell surface. As a treatment for advanced melanoma, the presumed mechanism of action of ipilimumab is to break down tolerance to the tumor-associated antigens in the melanoma. At the same time, this may result in decreased tolerance to self-antigens. A wide range of immune-mediated adverse events have been observed in patients treated with ipilimumab, including severe and potentially fatal inflammation of the liver, which is most commonly manifested as elevation of aminotransferases and hyperbilirubinemia. (See <a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy#H645631\" class=\"medical medical_review\">&quot;Toxicities associated with checkpoint inhibitor immunotherapy&quot;, section on 'Hepatotoxicity'</a>.)</p><p class=\"headingAnchor\" id=\"H919101937\"><span class=\"h3\">Pembrolizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pembrolizumab-drug-information\" class=\"drug drug_general\">Pembrolizumab</a> is a monoclonal antibody directed against the programmed cell death 1 protein (PD-1); is it approved for treatment of advanced melanoma [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/263\" class=\"abstract_t\">263</a>]. As with <a href=\"topic.htm?path=ipilimumab-drug-information\" class=\"drug drug_general\">ipilimumab</a>, a wide range of immune-mediated adverse events are reported, including severe and potentially fatal inflammation of the liver, although the risk appears to be lower overall compared with ipilimumab. (See <a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy#H645631\" class=\"medical medical_review\">&quot;Toxicities associated with checkpoint inhibitor immunotherapy&quot;, section on 'Hepatotoxicity'</a>.)</p><p class=\"headingAnchor\" id=\"H55\"><span class=\"h1\">COMBINATION CHEMOTHERAPY REGIMENS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of tumors are treated with combination rather than single agent therapy; typically, the individual agents have different mechanisms of action and toxicity profiles. The potential for greater tumor cell kill is sometimes accompanied by greater toxicity, including hepatotoxicity. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adjuvant therapy for breast cancer &ndash; Transient abnormalities in liver function tests (LFTs) are commonly observed in women receiving adjuvant chemotherapy for early stage breast cancer. (See <a href=\"topic.htm?path=adjuvant-chemotherapy-for-her2-negative-breast-cancer\" class=\"medical medical_review\">&quot;Adjuvant chemotherapy for HER2-negative breast cancer&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Approximately one-half to three-fourths of women receiving adjuvant CAF (<a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>, and <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a> [FU]) develop mild elevations in aminotransferases [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/264,265\" class=\"abstract_t\">264,265</a>]. These usually appear within the first three months of therapy, and they may persist, normalizing within one year of treatment cessation [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/265\" class=\"abstract_t\">265</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Adjuvant <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, and FU (CMF) has been associated with abnormal LFTs and focal defects on radionuclide liver scans [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/266,267\" class=\"abstract_t\">266,267</a>]; in one series, liver biopsy specimens showed severe local inflammation. Although rarely necessary, liver biopsy may be required in this setting to exclude tumor metastases and confirm the impression of drug-induced changes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=carmustine-drug-information\" class=\"drug drug_general\">Carmustine</a> plus <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a> &ndash; Severe and unexpected hepatotoxicity has been reported in patients treated with carmustine plus etoposide for either a brain tumor or relapsed Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/268,269\" class=\"abstract_t\">268,269</a>]. In one series, two of four patients receiving high doses of carmustine and etoposide for high-grade glioma developed fatal ascites, hyperbilirubinemia, and thrombocytopenia; one-third had transient ascites [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/268\" class=\"abstract_t\">268</a>]. This combination should be used only cautiously, if at all.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">Doxorubicin</a> and 6-mercaptopurine (6-MP) &ndash; The combination of doxorubicin and 6-MP in patients with refractory leukemia has produced unexpected hepatotoxicity. In a series of 11 cases, hyperbilirubinemia and elevations in aspartate transaminase (AST) and alkaline phosphatase followed each treatment course, although levels returned to baseline between treatments [<a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/270\" class=\"abstract_t\">270</a>]. At autopsy, intrahepatic cholestasis, hepatocellular necrosis, leukemic infiltration, and fatty change were noted in the liver. It was postulated that intracellular accumulation of doxorubicin might have potentiated the hepatotoxic effects of 6-MP.</p><p/><p class=\"headingAnchor\" id=\"H10042421\"><span class=\"h1\">LIVERTOX</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Additional information on chemotherapy-induced liver injury is available from the <a href=\"http://www.livertox.nih.gov/&amp;token=2zSk/UZTeO3J4oIM4h1Di9fg9utsfkFQlC3ryKItrySs0myBELRJEc3r1dIl6tjF&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">LiverTox</a>, a collaborative effort of the Liver Disease Research Branch of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) and the National Library of Medicine (NLM). <a href=\"http://www.livertox.nih.gov/&amp;token=2zSk/UZTeO3J4oIM4h1Di9fg9utsfkFQlC3ryKItrySs0myBELRJEc3r1dIl6tjF&amp;TOPIC_ID=2837\" target=\"_blank\" class=\"external\">LiverTox</a> is a freely accessible website that provides continuously updated comprehensive and evidence-based information about the clinical features of liver injury from drugs, dietary supplements, and herbal products along with a complete and annotated list of references.</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=toxic-hepatitis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Toxic hepatitis (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H56\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chemotherapy agents, either alone or in combination with other drugs and radiation, may cause indirect or direct hepatotoxicity. Furthermore, abnormal liver function may alter drug metabolism and increase the risk of extrahepatic toxicity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guidelines on dose modification for patients with preexisting hepatic disease are largely empiric. For some agents, including the vinca alkaloids, taxanes, <a href=\"topic.htm?path=procarbazine-drug-information\" class=\"drug drug_general\">procarbazine</a>, <a href=\"topic.htm?path=bosutinib-drug-information\" class=\"drug drug_general\">bosutinib</a>, <a href=\"topic.htm?path=bortezomib-drug-information\" class=\"drug drug_general\">bortezomib</a>, <a href=\"topic.htm?path=ixabepilone-drug-information\" class=\"drug drug_general\">ixabepilone</a>, <a href=\"topic.htm?path=ixazomib-drug-information\" class=\"drug drug_general\">ixazomib</a>, anthracyclines, <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a>, <a href=\"topic.htm?path=axitinib-drug-information\" class=\"drug drug_general\">axitinib</a>, <a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">lapatinib</a>, <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, <a href=\"topic.htm?path=nilotinib-drug-information\" class=\"drug drug_general\">nilotinib</a>, <a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a>, <a href=\"topic.htm?path=ponatinib-drug-information\" class=\"drug drug_general\">ponatinib</a>, <a href=\"topic.htm?path=ruxolitinib-drug-information\" class=\"drug drug_general\">ruxolitinib</a>, <a href=\"topic.htm?path=panobinostat-drug-information\" class=\"drug drug_general\">panobinostat</a>, and <a href=\"topic.htm?path=temsirolimus-drug-information\" class=\"drug drug_general\">temsirolimus</a>, there is agreement on the need for dose adjustment (or avoidance altogether) in patients with preexisting liver dysfunction in order to avoid excessive systemic toxicity (<a href=\"image.htm?imageKey=ONC%2F69104\" class=\"graphic graphic_table graphicRef69104 \">table 2</a> and <a href=\"image.htm?imageKey=ONC%2F81280\" class=\"graphic graphic_table graphicRef81280 \">table 6</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is less agreement on the need for dose reduction for other agents whose clearance is dependent upon liver metabolism, such as <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a>, <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>, <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, <a href=\"topic.htm?path=dactinomycin-drug-information\" class=\"drug drug_general\">dactinomycin</a>, <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a>, <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, <a href=\"topic.htm?path=procarbazine-drug-information\" class=\"drug drug_general\">procarbazine</a>, 6-mercaptopurine, <a href=\"topic.htm?path=crizotinib-drug-information\" class=\"drug drug_general\">crizotinib</a>, and <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infection with hepatitis B (HBV) or hepatitis C (HCV) is a common disorder that can be exacerbated with cytotoxic chemotherapy. A growing number of studies have demonstrated that prophylactic antiviral therapy can reduce both the incidence of reactivation and its severity in patients with chronic HBV infection. Patients who are hepatitis B surface antigen (HBsAg) positive and are receiving high-risk agents (eg, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, <a href=\"topic.htm?path=ofatumumab-drug-information\" class=\"drug drug_general\">ofatumumab</a>) warrant antiviral prophylaxis. While screening for evidence of HBV infection is recommended before initiation of chemotherapy that contains an anti-CD20 agent, the issue of universal screening prior to initiation of any potentially immunosuppressive chemotherapy remains controversial. (See <a href=\"#H9\" class=\"local\">'Hepatitis B'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/1\" class=\"nounderline abstract_t\">Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/2\" class=\"nounderline abstract_t\">Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005; 41:301.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/3\" class=\"nounderline abstract_t\">Chamilos G, Luna M, Lewis RE, et al. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin Ther 2007; 29:1980.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/4\" class=\"nounderline abstract_t\">Umrethia M, Ghosh PK, Majithya R, Murthy RS. 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity. Cancer Invest 2007; 25:117.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/5\" class=\"nounderline abstract_t\">Erichsen C, J&ouml;nsson PE. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 1984; 27:268.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/6\" class=\"nounderline abstract_t\">Greenstone MA, Dowd PM, Mikhailidis DP, Scheuer PJ. Hepatic vascular lesions associated with dacarbazine treatment. Br Med J (Clin Res Ed) 1981; 282:1744.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/7\" class=\"nounderline abstract_t\">Asbury RF, Rosenthal SN, Descalzi ME, et al. Hepatic veno-occlusive disease due to DTIC. Cancer 1980; 45:2670.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/8\" class=\"nounderline abstract_t\">Ceci G, Bella M, Melissari M, et al. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 1988; 61:1988.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/9\" class=\"nounderline abstract_t\">Sutherland CM, Krementz ET. Hepatic toxicity of DTIC. Cancer Treat Rep 1981; 65:321.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/10\" class=\"nounderline abstract_t\">F&eacute;aux de Lacroix W, Runne U, Hauk H, et al. Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment. Cancer Treat Rep 1983; 67:779.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/11\" class=\"nounderline abstract_t\">Raine J, Bowman A, Wallendszus K, Pritchard J. Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group. J Clin Oncol 1991; 9:268.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/12\" class=\"nounderline abstract_t\">Joensuu H, S&ouml;derstr&ouml;m KO, Nikkanen V. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report. Cancer 1986; 58:1437.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/13\" class=\"nounderline abstract_t\">Houghton AN, Shafi N, Rickles FR. Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report. Cancer 1979; 44:2324.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/14\" class=\"nounderline abstract_t\">Gill RA, Onstad GR, Cardamone JM, et al. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 1982; 96:58.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/15\" class=\"nounderline abstract_t\">Stoneham S, Lennard L, Coen P, et al. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 123:100.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/16\" class=\"nounderline abstract_t\">Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986; 104:651.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/17\" class=\"nounderline abstract_t\">Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14:806.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/18\" class=\"nounderline abstract_t\">Khozouz RF, Huq SZ, Perry MC. Radiation-induced liver disease. J Clin Oncol 2008; 26:4844.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/19\" class=\"nounderline abstract_t\">Hansen MM, Ranek L, Walbom S, Nissen NI. Fatal hepatitis following irradiation and vincristine. Acta Med Scand 1982; 212:171.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/20\" class=\"nounderline abstract_t\">Kun LE, Camitta BM. Hepatopathy following irradiation and adriamycin. Cancer 1978; 42:81.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/21\" class=\"nounderline abstract_t\">Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995; 24:759.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/22\" class=\"nounderline abstract_t\">B&eacute;nichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11:272.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/23\" class=\"nounderline abstract_t\">Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/24\" class=\"nounderline abstract_t\">Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1266.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/25\" class=\"nounderline abstract_t\">Yeo W, Mo FK, Chan SL, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007; 45:1382.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/26\" class=\"nounderline abstract_t\">Paul S, Saxena A, Terrin N, et al. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164:30.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/27\" class=\"nounderline abstract_t\">Voican CS, Mir O, Loulergue P, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 2016; 27:2172.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/28\" class=\"nounderline abstract_t\">Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61:703.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/29\" class=\"nounderline abstract_t\">Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol 2015; 33:2212.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/30\" class=\"nounderline abstract_t\">Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347:92.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/31\" class=\"nounderline abstract_t\">de Pree C, Giostra E, Galetto A, et al. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma. Ann Oncol 1994; 5:861.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/32\" class=\"nounderline abstract_t\">Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol) 2004; 16:204.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/33\" class=\"nounderline abstract_t\">Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9:156.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/34\" class=\"nounderline abstract_t\">Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46:2925.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/35\" class=\"nounderline abstract_t\">Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67:45.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/36\" class=\"nounderline abstract_t\">Faggioli P, De Paschale M, Tocci A, et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 1997; 82:38.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/37\" class=\"nounderline abstract_t\">Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83:1224.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/38\" class=\"nounderline abstract_t\">Khan S, Ramwani JJ, O'Brien PJ. Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation. Biochem Pharmacol 1992; 43:1963.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/39\" class=\"nounderline abstract_t\">Aubrey DA. Massive hepatic necrosis after cyclophosphamide. Br Med J 1970; 3:588.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/40\" class=\"nounderline abstract_t\">Walters D, Robinson RG, Dick-Smith JB, et al. Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide. Med J Aust 1972; 2:1070.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/41\" class=\"nounderline abstract_t\">Bacon AM, Rosenberg SA. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1982; 97:62.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/42\" class=\"nounderline abstract_t\">Goldberg JW, Lidsky MD. Cyclophosphamide-associated hepatotoxicity. South Med J 1985; 78:222.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/43\" class=\"nounderline abstract_t\">Snyder LS, Heigh RI, Anderson ML. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin Proc 1993; 68:1203.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/44\" class=\"nounderline abstract_t\">Shaunak S, Munro JM, Weinbren K, et al. Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine. Q J Med 1988; 67:309.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/45\" class=\"nounderline abstract_t\">Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 1984; 26:591.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/46\" class=\"nounderline abstract_t\">Matthias M, Saul G. [Clinical aspects of the excretion of alkylating cyclophosphamide metabolites in the urine of tumor bearing patients]. Onkologie 1978; 1:41.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/47\" class=\"nounderline abstract_t\">Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/48\" class=\"nounderline abstract_t\">Paschke R, Worst P, Brust J, Queisser W. [Hepatotoxicity with etoposide-ifosfamide combination therapy]. Onkologie 1988; 11:273.</a></li><li class=\"breakAll\">IFEX (sterile ifosfamide) package insert, Bristol-Myers Squibb.</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/50\" class=\"nounderline abstract_t\">Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10:337.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/51\" class=\"nounderline abstract_t\">Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/52\" class=\"nounderline abstract_t\">Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs 2012; 23:1099.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/53\" class=\"nounderline abstract_t\">Goldbecker A, Tryc AB, Raab P, et al. Hepatic encephalopathy after treatment with temozolomide. J Neurooncol 2011; 103:163.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/54\" class=\"nounderline abstract_t\">Dixit S, Hingorani M, Afzal P, Campbell AP. Temozolomide induced liver injury. Acta Neurol Belg 2011; 111:249.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/55\" class=\"nounderline abstract_t\">Sarganas G, Orzechowski HD, Klimpel A, et al. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol 2012; 14:541.</a></li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=temozolomide&amp;x=0&amp;y=0 (Accessed on June 16, 2014).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/57\" class=\"nounderline abstract_t\">Desmet VJ. Drug-induced liver disease: pathogenetic mechanisms and histopathological lesions. Eur J Med 1993; 2:36.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/58\" class=\"nounderline abstract_t\">Lazarus HM, Herzig RH, Graham-Pole J, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1:359.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/59\" class=\"nounderline abstract_t\">Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97:631.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/60\" class=\"nounderline abstract_t\">AMROMIN GD, DELIMAN RM, SHANBROM E. Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology 1962; 42:401.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/61\" class=\"nounderline abstract_t\">KOLER RD, FORSGREN AL. Hepatotoxicity due to chlorambucil; report of a case. J Am Med Assoc 1958; 167:316.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/62\" class=\"nounderline abstract_t\">Morris LE, Guthrie TH Jr. Busulfan-induced hepatitis. Am J Gastroenterol 1988; 83:682.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/63\" class=\"nounderline abstract_t\">Underwood JC, Shahani RT, Blackburn EK. Jaundice after treatment of leukemia with busulphan. Br Med J 1971; 1:556.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/64\" class=\"nounderline abstract_t\">Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 1983; 32:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/65\" class=\"nounderline abstract_t\">De Vita VT, Carbone PP, Owens AH Jr, et al. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 1965; 25:1876.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/66\" class=\"nounderline abstract_t\">Phillips GL, Fay JW, Herzig GP, et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 1983; 52:1792.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/67\" class=\"nounderline abstract_t\">Hoogstraten B, Gottlieb JA, Caoili E, et al. CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study. Cancer 1973; 32:38.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/68\" class=\"nounderline abstract_t\">Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79:108.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/69\" class=\"nounderline abstract_t\">Schein PS, O'Connell MJ, Blom J, et al. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 1974; 34:993.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/70\" class=\"nounderline abstract_t\">Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32:507.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/71\" class=\"nounderline abstract_t\">Pizzuto J, Avil&eacute;s A, Ramos E, et al. Cytosine arabinoside induced liver damage: histopathologic demonstration. Med Pediatr Oncol 1983; 11:287.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/72\" class=\"nounderline abstract_t\">George CB, Mansour RP, Redmond J 3rd, Gandara DR. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 1984; 54:2360.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/73\" class=\"nounderline abstract_t\">Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986; 70:1059.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/74\" class=\"nounderline abstract_t\">Kremer WB. Drugs five years later: cytarabine. Ann Intern Med 1975; 82:684.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/75\" class=\"nounderline abstract_t\">Kantarjian HM, Estey EH, Plunkett W, et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986; 81:387.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/76\" class=\"nounderline abstract_t\">Koren G, Beatty K, Seto A, et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992; 26:363.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/77\" class=\"nounderline abstract_t\">Bateman JR, Pugh RP, Cassidy FR, et al. 5-fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer 1971; 28:907.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/78\" class=\"nounderline abstract_t\">Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/79\" class=\"nounderline abstract_t\">Nikolic-Tomasevic Z, Jelic S, Cassidy J, et al. Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. Cancer Chemother Pharmacol 2005; 56:594.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/80\" class=\"nounderline abstract_t\">Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14:1735.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/81\" class=\"nounderline abstract_t\">Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5:1696.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/82\" class=\"nounderline abstract_t\">Hohn D, Melnick J, Stagg R, et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3:98.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/83\" class=\"nounderline abstract_t\">Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7:1646.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/84\" class=\"nounderline abstract_t\">Martin JK Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/85\" class=\"nounderline abstract_t\">Doria MI Jr, Shepard KV, Levin B, Riddell RH. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer 1986; 58:855.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/86\" class=\"nounderline abstract_t\">Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107:459.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/87\" class=\"nounderline abstract_t\">Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/88\" class=\"nounderline abstract_t\">Ito K, Ito H, Kemeny NE, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol 2012; 19:1609.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/89\" class=\"nounderline abstract_t\">Kemeny MM, Battifora H, Blayney DW, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202:176.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/90\" class=\"nounderline abstract_t\">Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/91\" class=\"nounderline abstract_t\">Pettavel J, Gardiol D, Bergier N, Schnyder P. Fatal liver cirrhosis associated with long-term arterial infusion of floxuridine. Lancet 1986; 2:1162.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/92\" class=\"nounderline abstract_t\">Shepard KV, Levin B, Karl RC, et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985; 3:161.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/93\" class=\"nounderline abstract_t\">Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 1999; 26:524.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/94\" class=\"nounderline abstract_t\">Aapro MS, Martin C, Hatty S. Gemcitabine--a safety review. Anticancer Drugs 1998; 9:191.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/95\" class=\"nounderline abstract_t\">Robinson K, Lambiase L, Li J, et al. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003; 48:1804.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/96\" class=\"nounderline abstract_t\">Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18:2780.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/97\" class=\"nounderline abstract_t\">Teusink AC, Hall PD. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother 2010; 44:750.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/98\" class=\"nounderline abstract_t\">Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Oncologist 2007; 12:1070.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/99\" class=\"nounderline abstract_t\">EINHORN M, DAVIDSOHN I. HEPATOTOXICITY OF MERCAPTOPURINE. JAMA 1964; 188:802.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/100\" class=\"nounderline abstract_t\">Shorey J, Schenker S, Suki WN, Combes B. Hepatotoxicity of mercaptopurine. Arch Intern Med 1968; 122:54.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/101\" class=\"nounderline abstract_t\">Berkovitch M, Matsui D, Zipursky A, et al. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics. Med Pediatr Oncol 1996; 26:85.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/102\" class=\"nounderline abstract_t\">McILVANIE SK, MACCARTHY JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood 1959; 14:80.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/103\" class=\"nounderline abstract_t\">CLARK PA, HSIA YE, HUNTSMAN RG. Toxic complications of treatment with 6-mercaptopurine; two cases with hepatic necrosis and intestinal ulceration. Br Med J 1960; 1:393.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/104\" class=\"nounderline abstract_t\">Adamson PC, Zimm S, Ragab AH, et al. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 1990; 26:343.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/105\" class=\"nounderline abstract_t\">Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/106\" class=\"nounderline abstract_t\">Rosman M, Bertino JR. Azathioprine. Ann Intern Med 1973; 79:694.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/107\" class=\"nounderline abstract_t\">Romagnuolo J, Sadowski DC, Lalor E, et al. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12:479.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/108\" class=\"nounderline abstract_t\">Small P, Lichter M. Probable azathioprine hepatotoxicity: a case report. Ann Allergy 1989; 62:518.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/109\" class=\"nounderline abstract_t\">Barrowman JA, Kutty PK, Ra MU, Huang SN. Sclerosing hepatitis and azathioprine. Dig Dis Sci 1986; 31:221.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/110\" class=\"nounderline abstract_t\">M&eacute;nard DB, Gisselbrecht C, Marty M, et al. Antineoplastic agents and the liver. Gastroenterology 1980; 78:142.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/111\" class=\"nounderline abstract_t\">Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases. Ann Intern Med 1976; 85:578.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/112\" class=\"nounderline abstract_t\">Satti MB, Weinbren K, Gordon-Smith EC. 6-thioguanine as a cause of toxic veno-occlusive disease of the liver. J Clin Pathol 1982; 35:1086.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/113\" class=\"nounderline abstract_t\">Krivoy N, Raz R, Carter A, Alroy G. Reversible hepatic veno-occlusive disease and 6-thioguanine. Ann Intern Med 1982; 96:788.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/114\" class=\"nounderline abstract_t\">Larrey D, Fr&eacute;neaux E, Berson A, et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988; 29:1265.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/115\" class=\"nounderline abstract_t\">Council on Drugs. Evaluation of two antineoplastic agents: pipobroman (Vercyte) and thioguanine. JAMA 1967; 200:139.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/116\" class=\"nounderline abstract_t\">Ruymann FB, Mosijczuk AD, Sayers RJ. Hepatoma in a child with methotrexate-induced hepatic fibrosis. JAMA 1977; 238:2631.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/117\" class=\"nounderline abstract_t\">Fried M, Kalra J, Ilardi CF, Sawitsky A. Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia. Cancer 1987; 60:2548.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/118\" class=\"nounderline abstract_t\">Kumari TP, Shanvas A, Mathews A, Kusumakumary P. Hepatocellular carcinoma: a rare late event in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2000; 22:289.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/119\" class=\"nounderline abstract_t\">Leme PR, Creaven PJ, Allen LM, Berman M. Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemother Rep 1975; 59:811.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/120\" class=\"nounderline abstract_t\">Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978; 23:68.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/121\" class=\"nounderline abstract_t\">Avil&eacute;s A, Herrera J, Ramos E, et al. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108:912.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/122\" class=\"nounderline abstract_t\">Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974; 33:19.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/123\" class=\"nounderline abstract_t\">Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 1993; 53:555.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/124\" class=\"nounderline abstract_t\">Johnson PJ, Dobbs N, Kalayci C, et al. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 1992; 65:751.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/125\" class=\"nounderline abstract_t\">Chan KK, Chlebowski RT, Tong M, et al. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 1980; 40:1263.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/126\" class=\"nounderline abstract_t\">Doroshow J, Chan K. Relationship between doxorubicin clearance and indocyanine green dye pharmacokinetics in patients with hepatic dysfunction (abstract). Proc Am Soc Clin Oncol 1982; 1:11.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/127\" class=\"nounderline abstract_t\">Benjamin RS. A practical approach to adriamycin (NSC 123127) toxicology. Cancer Chemother Rep 1975; 6:191.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/128\" class=\"nounderline abstract_t\">Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998; 34:33.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/129\" class=\"nounderline abstract_t\">Yarbro JW, Kennedy BJ. A comparison of the rate of recovery from inhibition of RNA synthesis in mouse liver and transplantable glioma. Cancer Res 1967; 27:1779.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/130\" class=\"nounderline abstract_t\">Gurevich I, Akerley W. Treatment of the jaundiced patient with breast carcinoma: case report and alternate therapeutic strategies. Cancer 2001; 91:660.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/131\" class=\"nounderline abstract_t\">Dobbs NA, Twelves CJ, Gregory W, et al. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer 2003; 39:580.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/132\" class=\"nounderline abstract_t\">Paciucci PA, Sklarin NT. Mitoxantrone and hepatic toxicity. Ann Intern Med 1986; 105:805.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/133\" class=\"nounderline abstract_t\">Vredenburgh JJ, McIntyre OR, Cornwell GG 3rd, et al. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. Med Pediatr Oncol 1988; 16:187.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/134\" class=\"nounderline abstract_t\">Chlebowski RT, Bulcavage L, Henderson IC, et al. Mitoxantrone use in breast cancer patients with elevated bilirubin. Breast Cancer Res Treat 1989; 14:267.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/135\" class=\"nounderline abstract_t\">Bedikian AY, Stroehlein J, Korinek J, et al. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer. Am J Clin Oncol 1983; 6:45.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/136\" class=\"nounderline abstract_t\">Wiseman LR, Spencer CM. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997; 10:473.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/137\" class=\"nounderline abstract_t\">Blum RH, Carter SK, Agre K. A clinical review of bleomycin--a new antineoplastic agent. Cancer 1973; 31:903.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/138\" class=\"nounderline abstract_t\">Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 1972; 77:861.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/139\" class=\"nounderline abstract_t\">Robert J, Barbier P, Manaster J, Jacobs E. Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice. Digestion 1968; 1:229.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/140\" class=\"nounderline abstract_t\">Lazarus HM, Gottfried MR, Herzig RH, et al. Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 1982; 49:1789.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/141\" class=\"nounderline abstract_t\">Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976; 3:121.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/142\" class=\"nounderline abstract_t\">van Hazel GA, Scott M, Rubin J, et al. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat Rep 1983; 67:805.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/143\" class=\"nounderline abstract_t\">Buroker TR, Kim PN, Baker LH, et al. Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas. Med Pediatr Oncol 1978; 4:35.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/144\" class=\"nounderline abstract_t\">Konits PH, Aisner J, van Echo DA, et al. Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 1981; 48:1295.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/145\" class=\"nounderline abstract_t\">Bukowski RM, Schacter LP, Groppe CW, et al. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 1982; 50:197.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/146\" class=\"nounderline abstract_t\">Tefft M, Traggis D, Filler RM. Liver irradiation in children: acute changes with transient leukopenia and thrombocytopenia. Am J Roentgenol Radium Ther Nucl Med 1969; 106:750.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/147\" class=\"nounderline abstract_t\">Ludwig R, Weirich A, Abel U, et al. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 1999; 33:462.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/148\" class=\"nounderline abstract_t\">Pritchard J, Raine J, Wallendszus K. Hepatotoxicity of actinomycin-D. Lancet 1989; 1:168.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/149\" class=\"nounderline abstract_t\">McClay E, Lusch CJ, Mastrangelo MJ. Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep 1987; 71:219.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/150\" class=\"nounderline abstract_t\">el Saghir NS, Hawkins KA. Hepatotoxicity following vincristine therapy. Cancer 1984; 54:2006.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/151\" class=\"nounderline abstract_t\">Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21:42.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/152\" class=\"nounderline abstract_t\">Desai ZR, Van den Berg HW, Bridges JM, Shanks RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982; 8:211.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/153\" class=\"nounderline abstract_t\">Van den Berg HW, Desai ZR, Wilson R, et al. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982; 8:215.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/154\" class=\"nounderline abstract_t\">Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59:32.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/155\" class=\"nounderline abstract_t\">Kitzen JJ, Puozzo C, de Jonge MJ, et al. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study. Eur J Cancer 2010; 46:266.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/156\" class=\"nounderline abstract_t\">Issell BF, Crooke ST. Etoposide (VP-16-213). Cancer Treat Rev 1979; 6:107.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/157\" class=\"nounderline abstract_t\">Tran A, Housset C, Boboc B, et al. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 1991; 12:36.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/158\" class=\"nounderline abstract_t\">Johnson DH, Greco FA, Wolff SN. Etoposide-induced hepatic injury: a potential complication of high-dose therapy. Cancer Treat Rep 1983; 67:1023.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/159\" class=\"nounderline abstract_t\">Chan HY, Meyers FJ, Lewis JP. High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 1987; 20:265.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/160\" class=\"nounderline abstract_t\">Perry MC, Moertel CG, Schutt AJ, et al. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. Cancer Treat Rep 1976; 60:1247.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/161\" class=\"nounderline abstract_t\">D'Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986; 46:2566.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/162\" class=\"nounderline abstract_t\">Arbuck SG, Douglass HO, Crom WR, et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986; 4:1690.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/163\" class=\"nounderline abstract_t\">Hande KR, Wolff SN, Greco FA, et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990; 8:1101.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/164\" class=\"nounderline abstract_t\">Aita P, Robieux I, Sorio R, et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 43:287.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/165\" class=\"nounderline abstract_t\">Stewart CF, Arbuck SG, Fleming RA, Evans WE. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8:1874.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/166\" class=\"nounderline abstract_t\">Stewart CF. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994; 34 Suppl:S76.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/167\" class=\"nounderline abstract_t\">Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996; 14:257.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/168\" class=\"nounderline abstract_t\">Liu B, Earl HM, Poole CJ, et al. Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 1995; 36:506.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/169\" class=\"nounderline abstract_t\">Huizing MT, Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13:381.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/170\" class=\"nounderline abstract_t\">Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54:386.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/171\" class=\"nounderline abstract_t\">Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6:1255.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/172\" class=\"nounderline abstract_t\">Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001; 27:221.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/173\" class=\"nounderline abstract_t\">Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995; 6:699.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/174\" class=\"nounderline abstract_t\">Panday VR, Huizing MT, Willemse PH, et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997; 24:S11.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/175\" class=\"nounderline abstract_t\">Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998; 16:1811.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/176\" class=\"nounderline abstract_t\">Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12:1621.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/177\" class=\"nounderline abstract_t\">Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14:1877.</a></li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23101 (Accessed on May 16, 2011).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/179\" class=\"nounderline abstract_t\">Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:58.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/180\" class=\"nounderline abstract_t\">Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs 1996; 7 Suppl 2:25.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/181\" class=\"nounderline abstract_t\">Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16:187.</a></li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23492 (Accessed on May 16, 2011).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/183\" class=\"nounderline abstract_t\">Minami H, Kawada K, Sasaki Y, et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 2009; 100:144.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/184\" class=\"nounderline abstract_t\">Syn NL, Wang L, Wong AL, et al. Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. Cancer Sci 2016; 107:173.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/185\" class=\"nounderline abstract_t\">Samur M. Docetaxel and liver dysfunction: is it absolutely contraindicated? Am J Clin Oncol 2001; 24:319.</a></li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=31271&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30d60d6d4e23472141 (Accessed on May 16, 2011).</li><li class=\"breakAll\">Witteveen, P, Marchetti, S, Mergui-Roelvink, M, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment (Abstract # 2582). J Clin Oncol 2010; 28:224s. Abstraact available online at http://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=48260 (Accessed on February 07, 2011).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/188\" class=\"nounderline abstract_t\">LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res 2012; 18:2954.</a></li><li class=\"breakAll\">Bortezomib (Velcade). FDA-approved manufacturer's package insert. US National Library of Medicine www.dailymed.nlm.nih.gov (Accessed on April 26, 2011).</li><li class=\"breakAll\">US Prescribing information for ixazomib available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf (Accessed on December 04, 2015).</li><li class=\"breakAll\">US prescribing information for carfilzomib available online at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6 (Accessed on December 04, 2015).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/192\" class=\"nounderline abstract_t\">Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/193\" class=\"nounderline abstract_t\">Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20:4303.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/194\" class=\"nounderline abstract_t\">Venook AP, Enders Klein C, Fleming G, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003; 14:1783.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/195\" class=\"nounderline abstract_t\">Meyerhardt JA, Kwok A, Ratain MJ, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:1439.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/196\" class=\"nounderline abstract_t\">Kramar A, Gourgou-Bourgade S, Ychou M. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan. J Clin Oncol 2005; 23:650; author reply 650.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/197\" class=\"nounderline abstract_t\">Cavalli F, Tschopp L, Sonntag RW, Zimmermann A. A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment. Cancer Treat Rep 1978; 62:2125.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/198\" class=\"nounderline abstract_t\">Hill JM, Loeb E, MacLellan A, et al. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 1975; 59:647.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/199\" class=\"nounderline abstract_t\">Pollera CF, Ameglio F, Nardi M, et al. Cisplatin-induced hepatic toxicity. J Clin Oncol 1987; 5:318.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/200\" class=\"nounderline abstract_t\">Hruban RH, Sternberg SS, Meyers P, et al. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 1991; 9:263.</a></li><li class=\"breakAll\">Christian MC. Two toxicities associated with carboplatin use: a. gross hematuria b. hepatic veno-occlusive disease. Department of Health &amp; Human Services bulletin, National Institutes of Health; National Cancer Institute, Bethesda, MD 1989.</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/202\" class=\"nounderline abstract_t\">Fakih MG. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology 2004; 67:222.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/203\" class=\"nounderline abstract_t\">Synold TW, Takimoto CH, Doroshow JH, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2007; 13:3660.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/204\" class=\"nounderline abstract_t\">Grenader T, Goldberg A, Gabizon A. Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel. Anticancer Drugs 2009; 20:845.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/205\" class=\"nounderline abstract_t\">Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969; 281:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/206\" class=\"nounderline abstract_t\">Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25:253.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/207\" class=\"nounderline abstract_t\">Muss HB, Spell N, Scudiery D, et al. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs 1990; 8:125.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/208\" class=\"nounderline abstract_t\">Douer D, Aldoss I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol 2014; 32:905.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/209\" class=\"nounderline abstract_t\">Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Petruska PJ. Procarbazine-induced hepatotoxicity: case report and review of the literature. Pharmacotherapy 2010; 30:540.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/210\" class=\"nounderline abstract_t\">McMaster KR 3rd, Hennigar GR. Drug-induced granulomatous hepatitis. Lab Invest 1981; 44:61.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/211\" class=\"nounderline abstract_t\">THURMAN WG, BLOEDOW C, HOWE CD, et al. A phase I study of hydroxyurea. Cancer Chemother Rep 1963; 29:103.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/212\" class=\"nounderline abstract_t\">Heddle R, Calvert AF. Hydroxyurea induced hepatitis. Med J Aust 1980; 1:121.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/213\" class=\"nounderline abstract_t\">McDonald GB, Tirumali N. Intestinal and liver toxicity of antineoplastic drugs. West J Med 1984; 140:250.</a></li><li class=\"breakAll\">Prescribing information for Arsenic trioxide available online at http://www.trisenox.com/pdf/TRISENOX_pi.pdf (Accessed on October 07, 2010).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/215\" class=\"nounderline abstract_t\">Ramalingam SS, Kummar S, Sarantopoulos J, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2010; 28:4507.</a></li><li class=\"breakAll\">Prescribing information for belinostat available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf?et_cid=34049616&amp;et_rid=789337055&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2014%2f206256lbl.pdf (Accessed on July 11, 2014).</li><li class=\"breakAll\">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468832.htm (Accessed on October 28, 2015).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/218\" class=\"nounderline abstract_t\">Paz-Ares L, L&oacute;pez-Pousa A, Poveda A, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2012; 30:729.</a></li><li class=\"breakAll\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf?et_cid=29953027&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203341lbl.pdf (Accessed on September 05, 2012).</li><li class=\"breakAll\">Full prescribing information for ceritinib  is available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf (Accessed on May 02, 2014).</li><li class=\"breakAll\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf (Accessed on December 15, 2015).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/222\" class=\"nounderline abstract_t\">Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007; 25:3055.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/223\" class=\"nounderline abstract_t\">Liu W, Makrauer FL, Qamar AA, et al. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007; 5:917.</a></li><li class=\"breakAll\">Alert letter available online at www.fda.gov/medwatch/safety/2008/tarceva_dhcp.letter.pdf (Accessed on April 26, 2011).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/225\" class=\"nounderline abstract_t\">Pellegrinotti M, Fimognari FL, Franco A, et al. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann Pharmacother 2009; 43:542.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/226\" class=\"nounderline abstract_t\">O'Bryant CL, Haluska P, Rosen L, et al. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol 2012; 69:605.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/227\" class=\"nounderline abstract_t\">Ho C, Davis J, Anderson F, et al. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 2005; 23:8531.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/228\" class=\"nounderline abstract_t\">Kim YH, Mio T, Mishima M. Gefitinib for non-small cell lung cancer patients with liver cirrhosis. Intern Med 2009; 48:1677.</a></li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18708&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30d60d6d4e23472141 (Accessed on May 16, 2011).</li><li class=\"breakAll\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf (Accessed on July 30, 2014).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/231\" class=\"nounderline abstract_t\">Kikuchi S, Muroi K, Takahashi S, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma 2004; 45:2349.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/232\" class=\"nounderline abstract_t\">Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26:563.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/233\" class=\"nounderline abstract_t\">O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/234\" class=\"nounderline abstract_t\">Cross TJ, Bagot C, Portmann B, et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006; 81:189.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/235\" class=\"nounderline abstract_t\">Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006; 91:ECR27.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/236\" class=\"nounderline abstract_t\">Azim HA Jr, Agbor-Tarh D, Bradbury I, et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 2013; 31:4504.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/237\" class=\"nounderline abstract_t\">Schaid DJ, Spraggs CF, McDonnell SK, et al. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol 2014; 32:2296.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/238\" class=\"nounderline abstract_t\">Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29:667.</a></li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808.</li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17796&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30d60d6d4e23472141 (Accessed on May 16, 2011).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/241\" class=\"nounderline abstract_t\">Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010; 102:1371.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/242\" class=\"nounderline abstract_t\">Motzer RJ, Johnson T, Choueiri TK, et al. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann Oncol 2013; 24:2927.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/243\" class=\"nounderline abstract_t\">Xu CF, Johnson T, Wang X, et al. HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. Clin Cancer Res 2016; 22:1371.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/244\" class=\"nounderline abstract_t\">Shibata SI, Chung V, Synold TW, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2013; 19:3631.</a></li><li class=\"breakAll\">Shibata S, Longmate J, Chung VM, et al. A phase I and pharmacokinetic single agent study of pazopanib in patients with advanced malignancies and varying degrees of liver dysfunction (Abstract 2571). J Clin Oncol 2010; 28:221s. Abstract available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=44621 (Accessed on January 06, 2012).</li><li class=\"breakAll\">US Food and Drug Administration (FDA)-approved manufacturer's package insert available online at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71 (Accessed on January 03, 2013).</li><li class=\"breakAll\">US Food and Drug Administration (FDA)-approved manufacturer's product information, available online at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7 (Accessed on October 04, 2012).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/248\" class=\"nounderline abstract_t\">Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27:1800.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/249\" class=\"nounderline abstract_t\">Meza-Junco J, Chu QS, Christensen O, et al. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 2009; 65:1.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/250\" class=\"nounderline abstract_t\">Peer CJ, Sissung TM, Kim A, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 2012; 18:2099.</a></li><li class=\"breakAll\">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=19678#nlm34068-7 (Accessed on August 05, 2010).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/252\" class=\"nounderline abstract_t\">Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278.</a></li><li class=\"breakAll\">US FDA drug approval summary for vandetanib in medullary thyroid cancer available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf (Accessed on April 25, 2011).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/254\" class=\"nounderline abstract_t\">Peveling-Oberhag J, Zeuzem S, Yong WP, et al. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. Clin Ther 2013; 35:215.</a></li><li class=\"breakAll\">US Food and Drug Administration (FDA)-approved manufacturer's labeling for everolimus available online at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=43629 (Accessed on June 17, 2011).</li><li class=\"breakAll\">US Food and Drug Administration (FDA)-approved prescribing information for trastuzumab emtansine available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf?et_cid=31141095&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125427lbl.pdf (Accessed on February 25, 2013).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/257\" class=\"nounderline abstract_t\">Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 2015; 373:621.</a></li><li class=\"breakAll\">US Food and Drug Administration (FDA)-approved prescribing information for ramucirumab available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477lbl.pdf (Accessed on April 25, 2014).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/259\" class=\"nounderline abstract_t\">Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20:3703.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/260\" class=\"nounderline abstract_t\">Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/261\" class=\"nounderline abstract_t\">Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009; 27:939.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/262\" class=\"nounderline abstract_t\">Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102:1406.</a></li><li class=\"breakAll\">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm (Accessed on September 08, 2014).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/264\" class=\"nounderline abstract_t\">Fetting JH, Gray R, Fairclough DL, et al. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol 1998; 16:2382.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/265\" class=\"nounderline abstract_t\">Larroquette CA, Hortobagyi GN, Buzdar AU, Holmes FA. Subclinical hepatic toxicity during combination chemotherapy for breast cancer. JAMA 1986; 256:2988.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/266\" class=\"nounderline abstract_t\">Vaughan WP, Wilcox PM, Alderson PO, et al. Hepatic toxicity of adjuvant chemotherapy for carcinoma of the breast. Med Pediatr Oncol 1979; 7:351.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/267\" class=\"nounderline abstract_t\">Hirvikoski PP, Kumpulainen EJ, Johansson RT. Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. Breast Cancer Res Treat 1997; 44:269.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/268\" class=\"nounderline abstract_t\">Wolff SN. High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity. Cancer Treat Rep 1986; 70:1464.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/269\" class=\"nounderline abstract_t\">Fleming DR, Wolff SN, Fay JW, et al. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. Leuk Lymphoma 1999; 35:91.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease/abstract/270\" class=\"nounderline abstract_t\">Minow RA, Stern MH, Casey JH, et al. Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and Adriamycin. Cancer 1976; 38:1524.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2837 Version 79.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H56\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">GENERAL ASPECTS OF DRUG-INDUCED HEPATOTOXICITY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Mechanisms</a><ul><li><a href=\"#H2739719\" id=\"outline-link-H2739719\">- Liposomal drug formulations</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">- Hepatic vascular injury</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Irradiation plus chemotherapy</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">Clinical presentation and diagnosis</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Natural history</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Impact of preexisting liver disease</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">- Hepatitis B</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Hepatitis C</a></li></ul></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">CYTOTOXIC AGENTS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Alkylating agents</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- Cyclophosphamide</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Ifosfamide</a></li><li><a href=\"#H1743491205\" id=\"outline-link-H1743491205\">- Temozolomide</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Other alkylating agents</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">Nitrosoureas</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Antimetabolites</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">- Cytarabine</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">- Fluorouracil and capecitabine</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Floxuridine</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">- Gemcitabine</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">- Mercaptopurine</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">- Azathioprine</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">- Thioguanine</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">- Methotrexate</a></li><li><a href=\"#H10245190\" id=\"outline-link-H10245190\">- Pemetrexed and pralatrexate</a></li></ul></li><li><a href=\"#H26\" id=\"outline-link-H26\">Antitumor antibiotics</a><ul><li><a href=\"#H27\" id=\"outline-link-H27\">- Anthracyclines</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">- Mitoxantrone</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">- Bleomycin</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">- Mitomycin</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">- Dactinomycin</a></li><li><a href=\"#H32\" id=\"outline-link-H32\">- Dacarbazine</a></li></ul></li><li><a href=\"#H33\" id=\"outline-link-H33\">Tubulin-acting agents</a><ul><li><a href=\"#H34\" id=\"outline-link-H34\">- Vinca alkaloids</a></li><li><a href=\"#H35\" id=\"outline-link-H35\">- Etoposide</a></li><li><a href=\"#H36\" id=\"outline-link-H36\">- Taxanes</a><ul><li><a href=\"#H714826\" id=\"outline-link-H714826\">Paclitaxel and docetaxel</a></li><li><a href=\"#H714836\" id=\"outline-link-H714836\">Cabazitaxel</a></li></ul></li><li><a href=\"#H37\" id=\"outline-link-H37\">- Ixabepilone</a></li><li><a href=\"#H742022\" id=\"outline-link-H742022\">- Eribulin</a></li></ul></li><li><a href=\"#H38\" id=\"outline-link-H38\">Miscellaneous agents</a><ul><li><a href=\"#H39\" id=\"outline-link-H39\">- Bortezomib and other proteasome inhibitors</a></li><li><a href=\"#H40\" id=\"outline-link-H40\">- Irinotecan and liposomal irinotecan</a></li><li><a href=\"#H41\" id=\"outline-link-H41\">- Platinum derivatives</a></li><li><a href=\"#H42\" id=\"outline-link-H42\">- Asparaginase</a></li><li><a href=\"#H43\" id=\"outline-link-H43\">- Procarbazine</a></li><li><a href=\"#H1507796661\" id=\"outline-link-H1507796661\">- Lenalidomide and pomalidomide</a></li><li><a href=\"#H44\" id=\"outline-link-H44\">- Hydroxyurea</a></li><li><a href=\"#H627314962\" id=\"outline-link-H627314962\">- Arsenic trioxide</a></li><li><a href=\"#H459304121\" id=\"outline-link-H459304121\">- Vorinostat, belinostat, and panobinostat</a></li><li><a href=\"#H605323938\" id=\"outline-link-H605323938\">- Trabectedin</a></li></ul></li></ul></li><li><a href=\"#H45\" id=\"outline-link-H45\">MOLECULARLY TARGETED AGENTS</a><ul><li><a href=\"#H11221439\" id=\"outline-link-H11221439\">Kinase inhibitors</a><ul><li><a href=\"#H217131934\" id=\"outline-link-H217131934\">- Axitinib</a></li><li><a href=\"#H35110980\" id=\"outline-link-H35110980\">- Bosutinib</a></li><li><a href=\"#H217132037\" id=\"outline-link-H217132037\">- Crizotinib, ceritinib, and alectinib</a></li><li><a href=\"#H217131947\" id=\"outline-link-H217131947\">- Dasatinib</a></li><li><a href=\"#H217132150\" id=\"outline-link-H217132150\">- Erlotinib and gefitinib</a></li><li><a href=\"#H15191128\" id=\"outline-link-H15191128\">- Ibrutinib</a></li><li><a href=\"#H1736672377\" id=\"outline-link-H1736672377\">- Idelalisib</a></li><li><a href=\"#H46\" id=\"outline-link-H46\">- Imatinib</a></li><li><a href=\"#H47\" id=\"outline-link-H47\">- Lapatinib</a></li><li><a href=\"#H83127096\" id=\"outline-link-H83127096\">- Lenvatinib</a></li><li><a href=\"#H217131983\" id=\"outline-link-H217131983\">- Nilotinib</a></li><li><a href=\"#H217131874\" id=\"outline-link-H217131874\">- Pazopanib</a></li><li><a href=\"#H1157198779\" id=\"outline-link-H1157198779\">- Ponatinib</a></li><li><a href=\"#H15667829\" id=\"outline-link-H15667829\">- Regorafenib</a></li><li><a href=\"#H3239500615\" id=\"outline-link-H3239500615\">- CDK 4/6 inhibitors</a></li><li><a href=\"#H48\" id=\"outline-link-H48\">- Sorafenib</a></li><li><a href=\"#H204884583\" id=\"outline-link-H204884583\">- Sunitinib</a></li><li><a href=\"#H104381194\" id=\"outline-link-H104381194\">- Vandetanib</a></li><li><a href=\"#H952085\" id=\"outline-link-H952085\">- Vemurafenib</a></li><li><a href=\"#H1142217\" id=\"outline-link-H1142217\">- Cobimetinib and trametinib</a></li></ul></li><li><a href=\"#H1577577405\" id=\"outline-link-H1577577405\">m-TOR inhibitors</a><ul><li><a href=\"#H54\" id=\"outline-link-H54\">- Everolimus</a></li><li><a href=\"#H204884575\" id=\"outline-link-H204884575\">- Temsirolimus</a></li></ul></li><li><a href=\"#H428907471\" id=\"outline-link-H428907471\">Ado-trastuzumab emtansine</a></li><li><a href=\"#H1978954832\" id=\"outline-link-H1978954832\">Brentuximab</a></li><li><a href=\"#H3859599982\" id=\"outline-link-H3859599982\">Elotuzumab</a></li><li><a href=\"#H236606549\" id=\"outline-link-H236606549\">Gemtuzumab ozogamicin</a></li><li><a href=\"#H244606019\" id=\"outline-link-H244606019\">Ramucirumab</a></li><li><a href=\"#H1577577467\" id=\"outline-link-H1577577467\">Immunotherapy</a><ul><li><a href=\"#H1577577479\" id=\"outline-link-H1577577479\">- Interferon alfa-2b (IFN-alfa-2b)</a></li><li><a href=\"#H89656322\" id=\"outline-link-H89656322\">- Pegylated interferon alfa (IFN-alfa)</a></li><li><a href=\"#H1577577448\" id=\"outline-link-H1577577448\">- Ipilimumab</a></li><li><a href=\"#H919101937\" id=\"outline-link-H919101937\">- Pembrolizumab</a></li></ul></li></ul></li><li><a href=\"#H55\" id=\"outline-link-H55\">COMBINATION CHEMOTHERAPY REGIMENS</a></li><li><a href=\"#H10042421\" id=\"outline-link-H10042421\">LIVERTOX</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H166917158\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H56\" id=\"outline-link-H56\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/2837|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/77533\" class=\"graphic graphic_table\">- NCI CTCAE v5 hepatobiliary toxicity</a></li><li><a href=\"image.htm?imageKey=ONC/69104\" class=\"graphic graphic_table\">- Chemo dose modify liver disease</a></li><li><a href=\"image.htm?imageKey=ONC/67680\" class=\"graphic graphic_table\">- FUdR dose modifications</a></li><li><a href=\"image.htm?imageKey=CARD/76992\" class=\"graphic graphic_table\">- Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers</a></li><li><a href=\"image.htm?imageKey=GAST/78401\" class=\"graphic graphic_table\">- Child-Pugh classification</a></li><li><a href=\"image.htm?imageKey=ONC/81280\" class=\"graphic graphic_table\">- Chemo dose mod molc agents</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-chemotherapy-for-her2-negative-breast-cancer\" class=\"medical medical_review\">Adjuvant chemotherapy for HER2-negative breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer\" class=\"medical medical_review\">Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-liver-biopsy\" class=\"medical medical_review\">Approach to liver biopsy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests\" class=\"medical medical_review\">Approach to the patient with abnormal liver biochemical and function tests</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-for-advanced-exocrine-pancreatic-cancer\" class=\"medical medical_review\">Chemotherapy for advanced exocrine pancreatic cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents\" class=\"medical medical_review\">Cutaneous side effects of conventional chemotherapy agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">Drug-induced liver injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drugs-and-the-liver-metabolism-and-mechanisms-of-injury\" class=\"medical medical_review\">Drugs and the liver: Metabolism and mechanisms of injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=enterotoxicity-of-chemotherapeutic-agents\" class=\"medical medical_review\">Enterotoxicity of chemotherapeutic agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">Extrapulmonary manifestations of alpha-1 antitrypsin deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-the-use-of-cyclophosphamide-in-rheumatic-diseases\" class=\"medical medical_review\">General principles of the use of cyclophosphamide in rheumatic diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gilbert-syndrome-and-unconjugated-hyperbilirubinemia-due-to-bilirubin-overproduction\" class=\"medical medical_review\">Gilbert syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatitis-b-virus-reactivation-associated-with-immunosuppressive-therapy\" class=\"medical medical_review\">Hepatitis B virus reactivation associated with immunosuppressive therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatotoxicity-associated-with-chronic-low-dose-methotrexate-for-nonmalignant-disease\" class=\"medical medical_review\">Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=liver-biochemical-tests-that-detect-injury-to-hepatocytes\" class=\"medical medical_review\">Liver biochemical tests that detect injury to hepatocytes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-potentially-resectable-colorectal-cancer-liver-metastases\" class=\"medical medical_review\">Management of potentially resectable colorectal cancer liver metastases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecularly-targeted-therapy-for-metastatic-melanoma\" class=\"medical medical_review\">Molecularly targeted therapy for metastatic melanoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noncirrhotic-portal-hypertension\" class=\"medical medical_review\">Noncirrhotic portal hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nonsurgical-local-treatment-strategies-for-colorectal-cancer-liver-metastases\" class=\"medical medical_review\">Nonsurgical local treatment strategies for colorectal cancer liver metastases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-neurologic-complications-of-non-platinum-cancer-chemotherapy\" class=\"medical medical_review\">Overview of neurologic complications of non-platinum cancer chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxic-hepatitis-the-basics\" class=\"medical medical_basics\">Patient education: Toxic hepatitis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preparative-regimens-for-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Preparative regimens for hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-chemotherapy-for-metastatic-colorectal-cancer-completed-clinical-trials\" class=\"medical medical_review\">Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer\" class=\"medical medical_review\">Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-for-her2-positive-metastatic-breast-cancer\" class=\"medical medical_review\">Systemic treatment for HER2-positive metastatic breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-for-advanced-hepatocellular-carcinoma\" class=\"medical medical_review\">Systemic treatment for advanced hepatocellular carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy\" class=\"medical medical_review\">Systemic treatment of metastatic breast cancer in women: Chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-of-metastatic-soft-tissue-sarcoma\" class=\"medical medical_review\">Systemic treatment of metastatic soft tissue sarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapeutic-use-and-toxicity-of-high-dose-methotrexate\" class=\"medical medical_review\">Therapeutic use and toxicity of high-dose methotrexate</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy\" class=\"medical medical_review\">Toxicities associated with checkpoint inhibitor immunotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-hepatic-sinusoidal-obstruction-syndrome-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-classical-hodgkin-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory classical Hodgkin lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-mantle-cell-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory mantle cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-multiple-myeloma\" class=\"medical medical_review\">Treatment of relapsed or refractory multiple myeloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory peripheral T cell lymphoma</a></li></ul></div></div>","javascript":null}